



Market Announcement

Appendix 4E and Annual Financial Report

Sydney, 26 August 2025 – In accordance with ASX Listing Rule 4.3A, Integrated Research Limited (**Company, IR**) (ASX:IRI) provides the attached Appendix 4E and Annual Financial Report for the year ended 30 June 2025.

Authorised for release by the Board of Integrated Research Limited.

Leanne Ralph
Company Secretary
Integrated Research Limited
ABN 76 003 588 449

About Integrated Research Limited (ASX: IRI). Integrated Research (IR) is the leading global provider of user experience and performance management solutions for payment transactions and collaborative systems. We create value through our real-time, scalable & extensible hybrid cloud platform and our deep domain knowledge to optimise operations of mission-critical systems and improve user experience through intelligent and actionable insights. We enable many of the world's largest organisations to simplify complexity and provide visibility over systems that millions of people can't live without – systems that allow them to transact and collaborate. For further information on IR, visit www.ir.com.



Appendix 4E

Full year report

Name of entity

INTEGRATED RESEARCH LIMITED		
ABN	Reporting period (year ended)	Previous corresponding period (year ended)
76 003 588 449	30 June 2025	30 June 2024

For announcement to the market

Extracts from this report for announcement to the market

				A\$000
Revenues from ordinary activities	Down	18%	to	68,256
Profit before tax attributable to members	Down	31%	to	18,422
Net profit for the year attributable to members	Down	51%	to	13,358

Dividends	Amount per security	Franked amount per security
2025 dividend declared	2.00c	2.00c
Previous corresponding period	2.00c	2.00c

On 26 August 2025, the directors declared a fully franked final dividend for the year ended 30 June 2025 of 2.0 cents per ordinary share and will be paid on 21 October 2025 with a record date of 04 September 2025.

	June 2025 cents	June 2024 cents
NTA backing		
Net tangible asset backing per ordinary security	56.73	50.61


Brief explanation of directional and percentage changes to profit:

Refer accompanying Group Financial Report.

Audit

This report is based on audited accounts.

For personal use only





Integrated Research Limited and Controlled Entities

ABN 76 003 588 449

ASX CODE IRI

Group Financial Report

For the year ended
30 June 2025

For personal use only

Contents	Page
Directors' Report	3
Remuneration Report	15
Financial Report	35
Notes to the Financial Report	40
Consolidated entity disclosure statement	72
Directors' Declaration	73
Auditor's Independence Declaration	74
Independent Auditor's Report	75

Directors' Report

The Directors present their report together with the Financial Report of Integrated Research Limited ("the consolidated entity" or "Integrated Research"), being the Company and its controlled entities, for the year ended 30 June 2025 and the Auditor's Report thereon.

Review of operations and activities

Principal activities

Integrated Research Limited's (the "Company" or "IR") principal activities are the design, development, implementation, and sale of software to monitor in real time the performance of business-critical computing, including Unified Communication networks and Payment networks.

Group overview

Integrated Research has a long heritage of providing performance monitoring, diagnostics, and management software solutions for business-critical computing environments.

Since its establishment in 1988, the Company has provided its Prognosis products to large organisations requiring high levels of computing performance and reliability.

Prognosis is an integrated suite of monitoring and management software, designed to give an organisation's management and technical personnel operational insight into, and optimise their operation of, HP NonStop, distributed system servers, Unified Communications ("UC"), and Payment environments and the business applications that run on these platforms.

Integrated Research has developed its Prognosis products around fault-tolerant, highly distributed software architecture, designed to achieve high levels of functionality, scalability, and reliability with a low total cost of ownership.

Integrated Research services customers in more than 44 countries through direct sales offices in the USA, UK, Germany, Singapore, and Australia, and via a global, channel-driven distribution network. Integrated Research's customer base consists of some of the world's largest organisations and includes banks, credit card companies, telecommunications carriers, technology companies, service providers and manufacturers.

The Company generates its revenue from licence fees, recurring maintenance, testing solutions and professional services. Revenue from the sale of licences where there are no post-delivery obligations is recognised at the date of the delivery. Revenue from maintenance contracts is recognised ratably over the service agreement. Revenue from professional services and testing solution services is recognised over the period the services are delivered.

Review and results of operations

Overview

The Company achieved an annual profit after tax of \$13.4 million in the financial year to 30 June 2025 (FY25). This represents a decrease of \$13.7 million on the prior year and is the result of an 18% decrease in revenue to \$68.3 million, and an increase in the effective tax rate, slightly offset by a 5% decrease in expenses to \$54.9 million. Robust cash conversion helped the Company increase its cash balance by 27% to \$40.6 million.

The decline in revenue performance was largely the consequence of a softer renewal book than in the previous year. As expected, the Company experienced stronger second half sales and revenue compared to the first half. Due to market uncertainty throughout the year, some of the anticipated new business opportunities experienced delays into FY26. This was most evident in the Americas, where new business growth slowed in the second half. Consequently, new business was lower than the preceding year. The Americas region contributed \$48.1 million - a 19% decline on the prior year, where Asia-Pacific contributed \$15.5 million and Europe \$4.7 million, down, 2% and 41%, respectively year on year. Demand generation and sales execution risk continued to be a focus for management.

Directors' Report cont.

The Company profited from currency gains of \$0.5 million (prior year loss of \$0.9 million) and benefited from other incomes of \$1.6 million (prior year \$0.1 million) which included \$1.2m from sale of the non-core testing solutions business. These amounts are included in other gains and losses of the Consolidated Statement of Comprehensive Income.

Revenue

The following table presents Company revenues for each of the relevant product groups:

In thousands of AUD	2025	2024	% Change
Collaborate	33,023	35,154	(6%)
Infrastructure	18,170	25,129	(28%)
Transact	13,280	18,434	(28%)
Professional services	3,783	4,575	(17%)
Total revenue	68,256	83,292	(18%)

Consistent with the softer FY25 renewals book, Collaborate revenue of \$33.0 million decreased by 6% over the prior year. The Collaborate market also continues to undergo significant changes as customers deploy cloud and hybrid environments, reducing their footprint of on-premise collaboration tools and contributing to churn risk. Recognising this, the Company launched Prognosis as a Service in late FY25. Prognosis as a Service provides clients with the same capabilities as the on premises version of Prognosis but hosted by the Company. This removes deployment and maintenance complexity for the client, reduces their cost of ownership, and aligns more generally with the enterprise adoption of hosted technology.

The constant currency net revenue retention rate for Collaborate in FY25 was 83% (2024: 86%). Licence fees for Collaborate were \$19.6 million, down 9% over the prior year. SaaS revenues for Collaborate were \$1.7 million, down 21% over the prior year, noting that unlike Collaborate on-premise, the revenue from products hosted by the Company (such as Prognosis as a Service) is recognised over the term of the contract.

Infrastructure revenue of \$18.2 million decreased by 28% over the prior year. Transact revenue of \$13.2 million, decreased by 28% over the prior year. The decline in Infrastructure and Transact revenue performance was also on account of a softer renewal book. Licence transactions sold during the year were closed on a multi-year term basis with maturities ranging from an average of three to five years.

The following table presents Company revenues for each of the relevant geographic segments in the underlying currencies:

	2025	2024	% Change
Asia Pacific (A\$'000)	15,471	15,830	(2%)
Americas (US\$'000)	30,884	39,138	(21%)
Europe (£'000)	2,358	4,128	(43%)

Asia Pacific revenue of \$15.5 million was down 2% over the prior year. The region achieved strong growth in Collaborate based on a large new business contract, however this was offset by underperformance in Infrastructure and Transact.

Americas revenue of US\$30.9 million, was down 21% over the prior year. The region experienced softer contract renewals and revenue decline to the prior year across all product lines. Year on year churn for Collaborate was broadly consistent with the prior year, while market uncertainty resulted in delays in new business deals expected to close in FY25. Transact and Infrastructure performance was mixed. Whilst a 5-year renewal of the largest customer underpinned strong renewal performance, market uncertainty contributed to delays in new business consistent with Collaborate.

Europe revenue of £2.4 million, was down 43% over the prior year, with all products underperforming. The Company is undertaking a review of its European business to assess growth opportunities.

Expenses

The following table presents the Company's cost base compared to the preceding year:

In thousands of AUD	2025	2024	% Change
Product and technology expenses	13,514	12,779	6%
Sales, professional services, and marketing expenses	34,056	38,679	(12%)
General and administration expenses	7,317	6,493	13%
Total expenses	54,887	57,951	(5%)

Total expenses were down 5% to \$54.9 million. The reduction in expense was primarily due to a reduction in sales expenses reflecting structural and sales leadership changes. Total staff numbers finished the year at 131 (2024: 142).

Gross spending on product and technology expenditure represents 20% of total revenue (2024: 15%):

In thousands of AUD	2025	2024	% Change
Gross product and technology expenses	13,514	12,779	6%
Capitalisation of development expenses	-	-	-
Amortisation of capitalised expenses	-	-	-
Net product and technology expenses	13,514	12,779	6%
Gross spend as a % of revenue	20%	15%	

Tax expense

Income tax was a net expense of \$5.1m for the year (2024: \$0.42m). The year on year increase was expected and reflects timing differences and a significant reduction in the availability and utilisation of R&D credits to offset the tax expense compared to the prior year, which benefited from utilisation of substantial brought forward R&D credits. The Company's effective tax rate for the year was 27.5%, where the prior year was 22.2% excluding brought forward R&D credits.

Shareholder returns

Returns to shareholders were as follows:

	2025	2024	2023
Net profit/(loss) (\$'000)	13,358	27,130	(29,226)
Basic EPS (cents)	7.56	15.57	(16.90)
Dividends declared per share (cents)	2.00	2.00	Nil
Dividend franking percentage	100%	100%	N/A
Return on equity	14%	37%	(40%)

Strategy and Priorities

FY25 was a transition year, the Company pivoting towards a product-led growth strategy and laying the foundations for sustainable growth over the medium term. While the product-led growth strategy continues to evolve, the Company has established clear innovation priorities and a defined product direction. This architecture incorporates the development of new capabilities aligned to the changing needs of large enterprise organizations, and the introduction of variable and consumption based pricing models to position for organic revenue growth over the medium to longer term.

The Company's product-led growth strategy also focuses specifically on leveraging Artificial Intelligence (AI) and machine learning (ML) to extract new value from existing and expanding data sets. Given the granularity and high fidelity nature of the data within Prognosis, the Company sees this as value generating and therefore highly strategic. Recognising the significant opportunities afforded by AI and ML, the Company established IR Labs. IR Labs is a dedicated innovation team focused on building new, AI and ML powered products and capabilities. The company intends to launch the first of its AI enabled products in the first half of FY26, part of an ongoing program to bring clients new value through innovation.

The Company experienced early signs of a positive shift in momentum across both new product releases and new business wins. This includes the successful release of the High Value Payments (HVP) product, the signing of a top 10 US bank as its first client, and the launch of Prognosis Elevate. Prognosis Elevate provides Prognosis as a service, hosted on behalf of the client by the Company; a demonstration of the product-led growth strategy aligning to the changing needs of large enterprise organisations. This alignment, and a more intentional approach to product differentiation are central to the Company's innovation agenda.

With the benefit of a strong cash position and clean balance sheet, the Company is committed to investment in product innovation for growth.

FY25 also saw the Company focus on execution fundamentals. Changes to the organization including recruiting for new capabilities in support of product-led growth, refocusing product, sales and marketing teams on new business growth and process redesign were introduced in FY25 and will continue to be a primary focus in FY26.

FY26 priorities are to continue to build on the foundations of product-led growth:

- new products and capabilities aligned to the changing needs of large enterprise organisations
- new AI/ML enabled products, including (but not limited to) products that leverage the data already harvested by Prognosis
- growth in the revenue contribution from new business (new clients and upsell to existing clients)

The material risks to delivery on our priorities continue to be:

- Competitors enhancing their tools to narrow the competitive advantage of the IR offers, including use of AI across both existing and emerging products;
- Changing customer requirements;
- Inflationary cost pressures both in the IR supply chain (wages growth, supplier price increases), and for customers resulting in an increase in competitive pricing in renewals and new business;
- Sales capability given the tight labour market, highly technical skillset, and time to productivity to effectively build a pipeline of opportunities and convert these to commercial deals;
- Product capability, given the tight labour market, highly technical skillset, and time to productivity to ensure our product offering and value proposition are relevant in the market; and
- Evolving geopolitical developments—particularly in the United States—that may adversely impact operations, new business growth and financial outcomes.

Directors

The Directors of the Company at any time during or since the end of the financial year are listed below:

Peter Lloyd, MAICD

Independent Non-Executive Director and Chairman

Peter was appointed Director in July 2010 and elected Chair in March 2021. He has over 45 years' experience in computing technology, having worked for both multinational computer hardware and software providers. Peter's experience in global markets includes executive management roles leading the Asia Pacific region as well as several stints in the U.S. For 35 years, Peter was specifically involved in the provision of payments solutions for banks and financial institutions. He is currently the proprietor of The Grayrock Group Pty Ltd, a management consultancy company focusing on the payments industry. Peter is a Non-Executive Director of privately held Taggle Pty Ltd.

Ian Lowe

Managing Director and Chief Executive Officer

Ian Lowe commenced as CEO and was appointed a Director in October 2024 and brings 25 years of leadership experience in the technology sector. Ian has led global companies providing big data enabled software solutions in diverse industries including Media, Finance and Sustainability, as a CEO and Director in both private and public companies. Prior to joining IR, Ian held executive roles including CEO at Wealth99, CEO at EP&T Global, and CEO and Executive Director at Adslot, where he led successful strategies encompassing product innovation, go-to-market, and corporate development.

Michael Hitz

Independent Non-Executive Director

Michael was appointed a Director in October 2023. His career spans roles from engineering communications infrastructure in energy, mining, and telecommunications, to corporate strategy, mergers and acquisitions and investing. Over the past five years Michael has worked with a leading pan-Asian fund to invest in public companies pursuing growth in payments, telecommunications, and energy. Prior to this, Michael was a Partner and Managing Director for The Boston Consulting Group, where he held roles including leading the technology, media, and telecommunications business.

Michael is a Director of The Institute for Economics and Peace Limited.

Michael is currently Chair of the Company's Technology & Innovation Committee.

Mark Brayan
Independent Non-Executive Director

Mark was elected a Director in November 2023. Mark has had an extensive career as Chief Executive Officer and Managing Director. He has run several Australian technology companies, public and private, in various domains including communications and artificial intelligence. Mark was previously the CEO of Soprano Design Pty Ltd, CEO and Managing Director of Appen Limited (ASX: APX), CEO and Managing Director of MineSite Technologies Pty Limited, and CEO and Managing Director of Integrated Research Limited (ASX: IRI). Mark is currently Chair and Non-Executive Director of SenSen Networks Limited (ASX: SNS), and Chair and Non-Executive Director of Shorthand Pty Ltd.

Mark has a Master of Business Administration (MBA) from the Australian Graduate School of Management (AGSM) and a First Class Honours Bachelor of Surveying from the University of New South Wales.

Mark is currently Chair of the Company's Nomination & Remuneration Committee.

Kate Greenhill
Independent Non-Executive Director

Kate was appointed a Director in April 2024 and is a fellow of the Institute of Chartered Accountants in Australia and a Graduate of the Australian Institute of Company Directors. Kate has over 30 years' experience in the financial services industry with extensive knowledge of finance and risk. As a former Partner with PwC, Kate has worked in both Australia and the UK providing assurance and advisory services to clients. She has experience as Chair of Audit, Risk & Compliance Committees.

Kate is currently a Director of Australian Ethical Investment Limited, an ASX Listed company. Kate is also a Director of Intersect Australia Limited, Australian Ethical Superannuation Pty Limited, and the Australian Ethical Foundation Limited.

Kate is currently Chair of the Company's Audit & Risk Committee.

Officers of the Company

Leanne Ralph
Company Secretary

Leanne was appointed in November 2024 and is a Fellow of the Governance Institute of Australia and a Graduate Member of the Australian Institute of Company Directors. Leanne is a highly experienced Company Secretary with a demonstrated history of working with ASX listed companies across a diverse range of industries. A strong business professional with a Bachelor of Business with Accounting & Finance majors from University of Technology.

Leanne was the founder and director of Boardworx Australia Pty Ltd until the sale of the business in July 2017. Since leaving the purchaser of Boardworx in January 2019 after working with her existing clients during that time, she has re-commenced providing outsourced Company Secretarial services to a select group of ASX listed entities, in addition to Integrated Research Limited, including Appen Limited, ImpediMed Limited and SenSen Networks Limited, and private groups, Estia Health and Alspec.

Leanne is also an independent non-executive director of Dicker Data Limited.

Christian Shaw, B. Bus CPA
Chief Financial Officer

Christian joined IR in January 2024 and is the Chief Financial Officer. He is responsible for Group Financials, Finance Planning and Analysis, People and Culture and Legal teams. He has over 30 years' of listed and private company experience as a senior finance and corporate services executive from a range of industries, including technology, minerals processing, financial services, telecommunications, and biotechnology. Christian possesses a strong operational, commercial, and strategic focus and has been the former CFO at AJG Australia, Multicom Resources, Unith Limited, Moko Social Media Limited and iCash Payment Systems Limited. He graduated with a Bachelor of Business from the University of Technology Sydney and is CPA qualified.

Resigning and Retiring Directors and Officers during the year

John Ruthven
Managing Director and Chief Executive Officer

John joined IR in July 2019. He resigned as Managing Director in July 2024 and Chief Executive Officer in September 2024. His employment ceased in January 2025.

Will Witherow, B.A., J.D.
General Counsel and Company Secretary

Will was appointed IR's General Counsel and Company Secretary in April 2022 and resigned as Company Secretary in November 2024. He continues to be employed by the Company as General Counsel.

Results

Profit for the year was \$13.4 million (2024: \$27.1m).

Dividends

Dividends

Dividends paid during the year

During the financial year ended 30 June 2025, the Company paid the following dividends on fully paid ordinary shares:

In thousands of AUD	Cents per share	Total amount	Franked/ unfranked	Record date	Date of payment
Final dividend for the year ended 30 June 2024	2.00	3,492	100% franked	03 September 2024	15 October 2024

Dividends declared subsequent to reporting date

On 26 August 2025, the Directors declared a fully franked final dividend for the year ended 30 June 2025 of 2.0 cents per ordinary share and will be paid on 21 October 2025 with a record date of 04 September 2025. The final dividend to be paid in October 2025 has not been recognised as a liability in the financial statements as at 30 June 2025.

In thousands of AUD	Cents per share	Total amount	Franked/ unfranked	Record Date	Date of payment
Final dividend declared for the year ended 30 June 2025	2.00	3,547	100% franked	04 September 2025	21 October 2025

Events subsequent to reporting date

Other than the dividend disclosed above, there has been no other transaction or event of a material or unusual nature that has arisen in the interval between the end of the financial year and the date of this report which is likely, in the opinion of the Directors of the Company, to affect significantly the operations of the Company, the results of those operations, or the state of affairs of the Company, in future financial years.

Future developments

Likely developments in the operations of the consolidated entity in future financial years and the expected results of those operations are referred to generally in the Review of Operations and Activities Report.

Further information on likely developments including expected results would be in the Directors' opinion, result in unreasonable prejudice to the Company and has therefore not been included in this Report.

Directors and Company Secretary

Details of current Directors' qualifications, experience and special responsibilities are set out on pages 7 to 8. Details of the company secretary and her qualifications are set out on page 8.

Officers who were partners of the audit firm during the financial year

No officers of the Company were partners of the current audit firm during the financial year.

Directors' meetings

The numbers of meetings of the Company's Board of Directors and of each Board committee held during the year ended 30 June 2025, and the numbers of meetings attended by each Director were:

	Board Meetings		Audit & Risk Committee Meetings		Nomination & Remuneration Committee Meetings		Technology & Innovation Meetings	
	A	B	A	B	A	B	A	B
Peter Lloyd	13	14	4	4	3	3	2	2
Ian Lowe	8	8	-	-	-	-	-	-
John Ruthven (until July 2024)	2	2	-	-	-	-	1	1
Michael Hitz	14	14	2	4	-	-	2	2
Mark Brayan	14	14	-	-	3	3	2	2
Kate Greenhill	14	14	4	4	3	3	-	-

A. Number of meetings attended.

B. Number of meetings held during the time the Directors held office or were a member of the Board or committee during the year.

State of affairs

In the opinion of the Directors there were no significant changes in the state of affairs of the consolidated entity that occurred during the financial year under review.

Environmental Regulation

The consolidated entity's operations are not subject to significant environmental regulations under either Commonwealth or State legislation.

Directors' interests

The relevant interest of each Director in the shares, options or performance rights over ordinary shares issued by the companies in the consolidated entity and other relevant bodies corporate, as notified by the Directors to the Australian Securities Exchange in accordance with S205G(1) of the Corporations Act 2001, at the date of this report is as follows:

	Ordinary shares in Integrated Research			Options	Performance rights
	Directly held	Beneficially held	Total	Number of options	Number of rights
Peter Lloyd	-	51,263	51,263	-	-
Ian Lowe	-	-	-	-	403,226
John Ruthven (Until July 2024) ⁽¹⁾	99,593	-	99,593	-	-
Mark Brayan	-	260,000	260,000	-	-
Kate Greenhill	-	-	-	-	-
Michael Hitz	-	-	-	-	-

1. Total Values represents holding on last day as Director.

Share options and performance rights

Options and performance rights granted to Directors and key management personnel

During or since the end of the financial year, the Company granted performance rights for no consideration over unissued ordinary shares in Integrated Research Limited to the following named Directors and executive officers of the consolidated entity as part of their remuneration:

	Number of performance rights granted	Performance hurdle	Exercise price	Expiry date
Executive Officers				
Ian Lowe	403,226	Yes	Nil	Aug 2027
Christian Shaw ¹	241,935	Yes	Nil	Aug 2027

¹ Apart from Performance right granted during the year, Christian Shaw also held 256,410 performance rights issued in prior year. Total numbers of performance rights held 498,345.

The performance rights were granted under the Integrated Research Limited Equity Plan Rules (established April 2023). Apart from interest in the performance rights disclosed above, they did not have any other interest in shares, options or performance rights over ordinary shares issued by the companies in the consolidated entity at the date of this report.

Unissued shares under options and performance rights

Unissued ordinary shares of Integrated Research Limited under options and performance rights at the date of this report are as follows:

Expiry date	Exercise price	Employee LTI	Executive LTI	Options	Total
Aug 2025	Nil	-	260,000	-	260,000
Sep 2025	Nil	980,592	-	-	980,592
Aug 2026	Nil	-	1,058,973	-	1,058,973
Sep 2026	Nil	2,671,950	-	-	2,671,950
Aug 2026	\$1.98	-	-	220,960	220,960
Aug 2027	Nil	-	1,562,105	-	1,562,105
Sep 2027	Nil	2,929,121	-	-	2,929,121
Total performance rights and options		6,581,663	2,881,078	220,960	9,683,701

Performance rights and options do not entitle the holder to participate in any share issues of the Company. Performance rights granted to the Company's employees under the Integrated Research Equity Plan Rules have a three-year vesting period including a service and performance condition, the details of the performance conditions for executive KMP are provided in the Remuneration Report. The performance conditions also apply to other Company executives.

Indemnification and insurance of officers and auditors

Indemnification

The Company has agreed to indemnify the Directors of the Company on a full indemnity basis to the full extent permitted by law, for all losses or liabilities incurred by the Director as an officer of the Company including, but not limited to, liability for negligence or for reasonable costs and expenses incurred, except where the liability arises out of conduct involving a lack of good faith.

To the extent permitted by law, the Company has agreed to indemnify its auditors, Ernst & Young, as part of the terms of its audit engagement agreement against claims by third parties arising from the audit (for an unspecified amount). No payment of this type has been made to Ernst & Young during or since the financial year.

Insurance

During the financial year Integrated Research Limited paid a premium to insure the Directors and executive officers of the consolidated entity and related bodies corporate.

The liabilities insured include costs and expenses that may be incurred in defending civil or criminal proceedings that may be brought against officers in their capacity as officers of the consolidated entity.

Remuneration report

The Company's Remuneration Report, which forms part of this Directors' Report, is on pages 15 to 34.

Directors' Report cont.

Corporate governance

A statement describing the Company's main corporate governance practices has been lodged with the Australian Securities Exchange dated 26 August 2025 and is available on the Company's website at <https://www.ir.com/about-us/policies-and-statements>.

Non-audit services

During the year Ernst & Young, the Company's auditor, has not performed other services in addition to their statutory duties as disclosed in note 7.

A copy of the auditors' independence declaration as required under Section 307C of the Corporations Act is on page 75 and forms part of the Directors' Report.

Rounding of amounts to nearest thousand dollars

The Company is of a kind referred to in ASIC Corporations Instrument 2016/191 and in accordance with that Class order, amounts in the Financial Report and the Directors' Report have been rounded off to the nearest thousand dollars, unless otherwise stated.

This report is made in accordance with a resolution of the Directors.



Peter Lloyd

Chair
26 August 2025
Sydney

Remuneration Report (audited)

Introduction from the Chair of the Nomination & Remuneration Committee

Dear Shareholder,

On behalf of the Board, I am pleased to present our Remuneration Report for FY25. This report describes our remuneration principles and framework for Directors and executives. It sets out the links between our remuneration framework and business strategy, performance and reward, and shareholder value creation.

Remuneration framework and objectives

Our remuneration framework is designed to motivate staff to execute and deliver on of our growth strategy: to maximise cash generation from new and existing customers with our existing Collaborate, Transact and Infrastructure product lines and re-invest capital into new product lines for sustainable, product-led growth.

The remuneration framework is designed with reference to industry practices and benchmarks, to attract and retain suitably qualified candidates, reward the achievement of strategic objectives, and align to shareholder value.

FY25 performance objectives and outcomes

The FY25 remuneration framework included potential reward for:

- Collaborate: new sales, renewals and gross churn reduction
- Transact and Infrastructure: overall Total Contract Value (TCV)
- New product development
- Overall business performance based on statutory revenue and EBITDA¹

The FY25 short-term incentives (STI) were subject to minimum achievement of financial and non-financial performance measures levels and included a mechanism designed to appropriately reward outperformance.

The long-term incentive (LTI) framework for executives in FY25 was similar to the FY24 LTI framework, with vesting of Performance Rights subject to a share price target, tested once over a 10-day VWAP trading period post publication of the FY27 Financial Report.

FY25's performance included some notable highlights, including:

- Successful launch of new products and securing of foundation clients (*High Value Payments* – signed top 10 US bank, *Prognosis Elevate* – Prognosis as a service)
- Development of new AI powered products - to be launched in 1H FY26
- Transact and Infrastructure, overall TCV achievement of 94% of target
- Robust cash conversion, cash growth of 27%
- FY25 Pro-forma revenue² steady compared to the prior year

FY25 targets reflect the Company's transition to a product led growth strategy, and in particular objectives focused on building new products and capturing new business revenue. The targets set were challenging in a year with a comparatively low renewals book compounded by delays in signing new business as result of global uncertainty.

In addition, we continue to maintain a strong balance sheet with no borrowings and improved cash balances compared to FY24.

Further details of STI and LTI objectives are in the tables below.

¹ EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortisation) is a non-IFRS measure used to evaluate the Company's operating performance by focusing on profit from core operations and excluding the effects of capital structure, tax rates, and non-cash accounting items like depreciation and amortisation.

² Pro forma Revenue is an alternative non-IFRS measure calculated as pro forma subscription revenue plus other non-recurring revenue streams such as perpetual licence fees, professional services, and one-time testing services. Pro forma subscription revenue provides a view of underlying performance by restating term licence on a recurring subscription basis (i.e. over time) plus other recurring revenues such as maintenance fees and cloud services.

CEO and MD remuneration

The Company transitioned CEO and MD's during FY25, with the exit of John Ruthven and the appointment of Ian Lowe. To support a smooth transition, the Company undertook a four-month transition period. As a consequence, aggregate, total fixed remuneration for the CEO and MD's increased by 28% in FY25.

The STI for John Ruthven, as the outgoing CEO and MD was agreed pro rata, for the first quarter of FY25 only, as part of the CEO transition. The STI achieved by the outgoing CEO was 75% of the total STI payment opportunity for the first quarter and based on achieving 100% of the TCV and cash generation targets and 0% of the EBITDA target.

The STI outcome for Ian Lowe, as the incoming CEO and MD applied pro rata from his October 1, 2024, commencement date. The STI outcome was 42.5% of the STI payment opportunity, based on some, but not all targets being met. Ian has positively driven the business reset to focus on product innovation. The overall TCV and profit results were disappointing, reflective of challenging targets weighted to new business during a period of change and global uncertainty. Further details follow in the Remuneration Report.

LTI granted to John Ruthven as outgoing CEO and MD had the following active plans during FY25:

- Share Options granted under the Company's FY22 LTI plan, with a total of 655,809 Options being available for exercise with an exercise price of A\$1.98 per Option and an expiry date for all Options of 31 August 2026. All these Options lapsed in January 2025, upon cessation of employment.
- Performance Rights granted under the Company's FY23 LTI plan, with a first-year share price hurdle of A\$0.80 and re-test features in subsequent years. All these Performance Rights lapsed in January 2025, upon cessation of employment.

LTI granted to Ian Lowe as incoming CEO and MD had the following active plans during FY25:

- Performance Rights granted under the Company's FY25 LTI plan, with a total of 403,226 Performance Rights being available for exercise and conversion into 403,226 ordinary shares in a single tranche subject to a three-year service condition and a three-year share price performance condition being met. The share price performance condition being A\$1.80, calculated using a share price VWAP for the 10 trading days following the release of the Company's FY27 earnings.

On behalf of the Board, we recommend this report to you and welcome any feedback you may have.



Mark Brayan

Chair of the Nomination & Remuneration Committee

1. Persons included in the Remuneration Report

KMP, including Directors, have authority and responsibility for planning, directing, and controlling the activities of the Company and the consolidated entity. The following were KMP of the Company at any time during the reporting period, and unless otherwise indicated were KMP for the entire period:

1.1. Executive KMP

As of the current year, the Nomination & Remuneration Committee (Committee) assessed the Executive KMP to include the following executive roles.

Executive KMP	Role	Appointed/Resigned
Ian Lowe	Chief Executive Officer and Managing Director	October 2024
Christian Shaw	Chief Financial Officer	March 2024 ¹
John Ruthven	Chief Executive Officer and Managing Director	July 2024 resigned as Managing Director September 2024 resigned as CEO January 2025 ceased employment ²

¹ Joined the company in January 2024 but assumed role of CFO March 2024

² Gardening leave from October 2024 to January 2025

1.2. Independent Non-Executive Directors

Directors	Role	Appointed
Peter Lloyd	Independent Non-Executive Director and Chair	Director from July 2010 Chair from March 2021
Mark Brayan	Independent Non-Executive Director	November 2023
Kate Greenhill	Independent Non-Executive Director	April 2024
Michael Hitz	Independent Non-Executive Director	October 2023

2. Executive remuneration

2.1. Remuneration framework

The remuneration framework set out below considers the capability and experience of the Executive KMP, their ability to control business performance, and the Company's performance.

	Fixed remuneration	Short-term incentive (STI)	Long-term incentive (LTI)
Purpose	To ensure that fixed remuneration is competitive in the marketplace to attract and retain executives.	To provide focus on annual objectives and align remuneration outcomes with achievement of key priorities.	To provide focus on long-term performance and align remuneration outcomes with the experience of shareholders.
Delivery	Base salary plus superannuation and any fringe benefits.	The STI is provided as an annual award paid in cash. Performance measures are set and assessed through a balanced scorecard that varies with position. The target levels of performance set by the Board are challenging and driven by the annual budget and longer-term strategic plan.	The LTI is provided as either options or performance rights over ordinary shares of the Company that vest over 3 years subject to performance and service conditions. LTI awards are granted annually. The LTI performance measures set by the Board are aligned with value creation for shareholders.
Performance period	N/A	12 months	3 years

For personal use only

2.2. FY25 Short-term incentive (STI)

The FY25 STI framework is described below.

Feature	Description
Participants	Executive Leadership Team, including Executive KMP
Award basis	The Committee is responsible for setting performance measures for the CEO and MD, and for approving the measures for the other executives who report to the CEO and MD. The performance measures for executives generally include key metrics relating to the Company and the individual, and may include financial, people, customer, and strategy. The measures are chosen as they directly align the individual executive's reward to the key metrics of the Company and its strategy and performance. At the end of the performance period the Committee assesses the actual performance against the targets set at the beginning of the financial year. A percentage of the predetermined target opportunity for each performance measure is awarded depending on results. The Committee recommends the award be paid for approval by the Board. STI awards are paid in cash.
Performance measures	<p>Performance measures are set and assessed through a balanced scorecard that varies with the position. The target levels of performance set by the Board are challenging and driven by the annual budget and longer-term strategic plan. Performance measures may include financial and non-financial measures.</p> <p>The performance measures in FY25 were:</p> <ul style="list-style-type: none"> • Product innovation in pursuit of new revenue • Total Contract Value (TCV) by product • New Business Contract Value - Collaborate • Revenue Churn reduction - Collaborate • Statutory Revenue • EBITDA
Performance period	Performance is measured over the financial year. To provide executives with additional focus and attention to deliver key priorities for FY25, the Committee may set targets for both half-year (H1) and full-year results for each performance measure.
Scorecard operation	Each performance measure in scorecards has a vesting scale with threshold requirements. Outcomes below threshold requirements result in nil payments. Outcomes above threshold are paid at 50% of the STI payment opportunity for 90% achievement, on a pro-rata linear basis from 90-125% achievement, and is capped at 150% of payment opportunity above 125% achievement.
Payment timing	Awards are paid following assessment of the performance measures based on audited full-year results.
Treatment on termination	Unvested STI awards are forfeited on termination of employment.

2.3. FY25 Long-term incentive (LTI)

The FY25 LTI framework is described below.

Feature	Description
Participants	Executive Leadership Team, including Executive KMP.
Payment vehicle	Performance Rights which are rights to acquire ordinary shares in the Company for nil consideration subject to achievement of vesting conditions.
Award basis	The number of Performance Rights granted to participants is calculated by dividing the face value of the LTI opportunity for FY25 by the Company's 10-day VWAP after release of FY24 full-year results, being A\$0.62. Performance Rights are granted in one tranche.
Vesting period	The Vesting Date is 10 trading days following the release of the Company's FY27 Financial Report. Any Performance Rights which do not meet the performance conditions upon the Vesting Date will automatically lapse.
Performance conditions	<p>Vesting of Performance Rights is subject to achievement of the share price performance hurdle set out below.</p> <p>Vesting: Where the Company's share price, calculated using the closing share price VWAP for the 10 trading days following the release of the Company's FY27 Financial Report, is equal to or greater than A \$1.80, the percentage of Performance Rights that will vest against the Performance Condition is 100%.</p> <p>Nil Vesting: Where the Company's share price, calculated using the closing share price VWAP for the 10 trading days following the release of the Company's FY27 Financial Report, is less than A\$1.80, the percentage of Performance Rights that will vest against the Performance Condition is Nil.</p>
Treatment on termination	Unvested Performance Rights are forfeited on cessation of employment, unless the Performance Rights have met the performance conditions and employment is terminated due to death, disability, or redundancy.
Change of control	In the event of a takeover or other change of control, any unvested Performance Rights will vest at the discretion of the Board.
Malus and clawback	The awards are subject to malus considerations by the Board and in relation to serious and material matters may be subject to a reduction or adjustment prior to exercise or clawback. In the event of fraud, dishonesty, or breach of obligations (including legal and statutory non-compliance), the Board may take action to ensure that no unfair benefit is obtained.

FY24 LTI

The FY24 LTI framework is described below.

Feature	Description
Participants	Executive Leadership Team, including Executive KMP and excluding the CEO and MD as the LTI was not approved at the Company's 2023 AGM.
Payment vehicle	Performance Rights which are rights to acquire ordinary shares in the Company for nil consideration subject to achievement of vesting conditions.
Award basis	The number of Performance Rights granted to participants is calculated by dividing the face value of the LTI opportunity for FY24 by the Company's 10-day VWAP after release of FY23 full-year results, being A\$0.39. Performance Rights are granted in three equal tranches.
Vesting period	Performance Rights vest on 31 August 2026 (Vesting Date) subject to achievement of service conditions and performance conditions set out below. Performance Rights that vest are automatically exercised for shares.
Performance conditions	Vesting of Performance Rights in each tranche is subject to the achievement of share price hurdles set out below.

Tranche 1

Testing in 2024: Where the Company's share price, calculated using the closing share price VWAP of the Company for the ten trading days following the release of the Company's FY24 Financial Report is equal to or greater than A\$0.80, 100% of Tranche 1 Performance Rights will vest in August 2026 if the service condition is met.

Outcome: *Tranche 1 failed to meet the A\$0.80 share price hurdle.*

Tranche 1 Performance Rights which do not meet the Performance Condition of A\$0.80 on 31 August 2024 may be carried forward for retesting against (i) the Tranche 2 Performance Condition of A\$1.20 on 31 August 2025, or (ii) the Tranche 3 Performance Condition of A\$1.60 on 31 August 2026.

There is no retesting of Performance Rights after the Vesting Date.

Tranche 2

Testing in 2025: Where the Company's share price, calculated using the closing share price VWAP of the Company for the ten trading days following the release of the Company's FY25 Financial Report is equal to or greater than A\$1.20, 100% of Tranche 2 Performance Rights will vest in August 2026 if the service condition is met.

Tranche 2 Performance Rights which do not meet the Performance Condition of A\$1.20 on 31 August 2025 may be carried forward for retesting against the Tranche 3 Performance Condition of A\$1.60 on 31 August 2026.

There is no retesting of Performance Rights after the Vesting Date.

For personal use only

	<p>Tranche 3 Performance Rights which do not meet the Performance Condition of A\$1.60 on 31 August 2026 will lapse. Similarly, any Tranche 1 or Tranche 2 Performance Rights which have been carried forward for retesting against the Tranche 3 Performance Condition of A\$1.60 on 31 August 2026 will also lapse.</p> <p>There is no retesting of Performance Rights after the Vesting Date.</p>
Treatment on termination	Unvested Performance Rights are forfeited on cessation of employment, unless the Performance Rights have met the performance conditions and employment is terminated due to death, disability, or redundancy.
Change of control	In the event of a takeover or other change of control, any unvested Performance Rights will vest at the discretion of the Board.
Malus and clawback	The awards are subject to malus considerations by the Board and in relation to serious and material matters may be subject to a reduction or adjustment prior to exercise or clawback. In the event of fraud, dishonesty, or breach of obligations (including legal and statutory non-compliance), the Board may take action to ensure that no unfair benefit is obtained.
Current Status:	Tranche 1 tested in FY25 failed to meet the A\$0.80 share price hurdle.

FY23 LTI

The FY23 LTI framework is described below.

Feature	Description
Participants	Executive Leadership Team, including Executive KMP
Payment vehicle	Performance Rights which are rights to acquire ordinary shares in the Company for nil consideration subject to achievement of vesting conditions.
Award basis	The number of Performance Rights granted to participants is calculated by dividing the face value of the LTI opportunity for FY23 by the Company's 10-day VWAP to 31 August 2022. The 10-day VWAP on that date was A\$0.50. Performance Rights are granted in three equal tranches.
Vesting period	Performance Rights vest on 31 August 2025 (Vesting Date) subject to achievement of service conditions and performance conditions set out below. Performance Rights that vest are automatically exercised for shares.
Performance conditions	Vesting of Performance Rights in each tranche is subject to the achievement of share price hurdles set out below.

Tranche 1

Testing in 2023: Where the 10-day VWAP immediately prior to and including 31 August 2023 is equal to or greater than A\$0.80, 100% of Tranche 1 Performance Rights will vest in August 2025 if the service condition is met.

Outcome: *Tranche 1 failed to meet the A\$0.80 share price hurdle.*

	<p>Tranche 1 Performance Rights which did not meet the Performance Condition of A\$0.80 on 31 August 2023 may be carried forward for retesting against (i) the Tranche 2 Performance Condition of A\$1.20 on 31 August 2024, or (ii) the Tranche 3 Performance Condition of A\$1.60 on 31 August 2025.</p> <p>There is no retesting of Performance Rights after the Vesting Date.</p> <p>Tranche 2</p> <p>Testing in 2024: Where the 10-day VWAP immediately prior to and including 31 August 2024 is equal to or greater than A\$1.20, 100% of Tranche 2 Performance Rights will vest in August 2025 if the service condition is met.</p> <p>Outcome: <i>Tranche 2 failed to meet the A\$1.20 share price hurdle.</i></p> <p>Tranche 2 Performance Rights which did not meet the Performance Condition of A\$1.20 on 31 August 2024 may be carried forward for retesting against the Tranche 3 Performance Condition of A\$1.60 on 31 August 2025.</p> <p>There is no retesting of Performance Rights after the Vesting Date.</p> <p>Tranche 3</p> <p>Testing in 2025: Where the 10-day VWAP immediately prior to and including 31 August 2025 is equal to or greater than A\$1.60, 100% of Tranche 3 Performance Rights will vest in August 2025 if the service condition is met.</p> <p>Tranche 3 Performance Rights which do not meet the Performance Condition of A\$1.60 on 31 August 2025 will lapse. Similarly, any Tranche 1 or Tranche 2 Performance Rights which have been carried forward for retesting against the Tranche 3 Performance Condition of A\$1.60 on 31 August 2025 will also lapse.</p> <p>There is no retesting of Performance Rights after the Vesting Date.</p>
Treatment on termination	<p>Unvested Performance Rights are forfeited on cessation of employment, unless the Performance Rights have met the performance conditions and employment is terminated due to death, disability, or redundancy.</p>
Change of control	<p>In the event of a takeover or other change of control, any unvested Performance Rights will vest at the discretion of the Board.</p>
Malus and clawback	<p>The awards are subject to malus considerations by the Board and in relation to serious and material matters may be subject to a reduction or adjustment prior to exercise or clawback. In the event of fraud, dishonesty, or breach of obligations (including legal and statutory non-compliance), the Board may take action to ensure that no unfair benefit is obtained.</p>
Current Status:	<p>Tranche 1 tested in FY24 failed to meet the A\$0.80 share price hurdle.</p> <p>Tranche 2 tested in FY25 failed to meet the A\$1.20 share price hurdle.</p>

For personal use only

FY22 LTI

The FY22 LTI framework is described below.

Feature	Description
Participants	Executive Leadership Team, including Executive KMP
Payment vehicle	Options which are rights to acquire ordinary shares in the Company at the exercise price of A\$1.98 per option if the service conditions are met.
Award basis	Quantity issued is a percentage of executive remuneration.
Vesting period	Options vest in three equal tranches over a three-year period, with tranche 1 vesting in August 2022. All Options have an expiry date of 31 August 2026. Any Options which are not exercised by the Expiry date will automatically lapse.
Service conditions	Exercise of Options is subject to continuous employment.
Treatment on termination	Options are forfeited on cessation of employment, unless terminated due to death, disability, or redundancy.
Change of control	In the event of a takeover or other change of control, any unexercised Options will exercise at the discretion of the Board.
Malus and clawback	The awards are subject to malus considerations by the Board and in relation to serious and material matters may be subject to a reduction or adjustment prior to exercise or clawback. In the event of fraud, dishonesty, or breach of obligations (including legal and statutory non-compliance), the Board may take action to ensure that no unfair benefit is obtained.
Current Status	The final tranche of Options vested on 31 August 2024. All outstanding Options have an expiry date of 31 August 2026. No options have been exercised under this plan. Options Issued to employees who ceased employment have been cancelled.

2.4. FY25 executive remuneration opportunity

(AUD)	CEO and Managing Director	CFO
Fixed remuneration	\$550,000 ¹	\$404,932
STI opportunity (at target) ¹	\$250,000 ^{1,2}	\$100,000 ²
LTI opportunity (face value) ³	\$250,000	\$150,000

Notes



1. Opportunity on full-year basis.
2. The STI opportunity is capped for stretch outcomes at 150% payment.
3. The number of Performance Rights granted to participants is calculated by dividing the face value of the LTI opportunity for FY25 by the Company's 10-day VWAP after release of FY24 full-year results, being A\$0.62. Performance Rights are granted in one tranche.

3. Company performance and remuneration outcomes

In considering the Company's performance and benefits for shareholder wealth, the Committee has regard to the following indices in respect of the current financial year and the previous two financial years:

Three-year selected financial indices of the Company

	2025	2024	2023
Total contract value (\$'000)	67,273	83,869	68,499
Net cashflow before financing activities (\$'000)	12,798	15,317	7,162
Pro forma EBITDA (\$'000)	21,497	16,733	17,575
Dividends paid (\$'000)	3,492	-	-
Closing share price	\$0.42	\$0.93	\$0.39
Pro forma EBITDA incline/(decline) %	28%	(5%)	(28%)
Executive KMP remuneration (\$'000)	1,339	1,430	1,847



Two of the financial indices shown in the tables above are Total Contract Value (TCV) and Cashflow. The Committee considers these two financial performance metrics as Key Performance Indicators (KPIs) in setting the STI element of the KMP remuneration package. When adjusting the above charts for the co-existence of two CEOs for 4 months and the termination of the outgoing CEO in FY25, Executive KMP's remuneration down trended in FY25 due mostly to a reduction in incentive remuneration, reflecting alignment with the overall performance outcomes set for FY25. The Committee considers that the above performance-linked structure is generating the desired outcomes.

Reconciliation of Net profit after Tax (NPAT) to EBITDA & Pro forma EBITDA

	2025	2024
Net Profit after Tax (NPAT)	13,358	27,130
Income tax expense/(benefit)	5,064	(416)
Finance Income	(2,961)	(2,225)
Depreciation & Amortisation	421	112
EBITDA ¹	15,882	24,601
Cost deferral related to over time revenue	(451)	671
Over-time revenue conversion	6,066	(8,539)
Pro forma EBITDA ²	21,497	16,733

¹ EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortisation) is a non-IFRS measure used to evaluate the Company's operating performance by focusing on profit from core operations and excluding the effects of capital structure, tax rates, and non-cash accounting items like depreciation and amortisation.

² Pro forma EBITDA is an alternative non-IFRS measure calculated as pro forma revenue less expenses (variable compensation adjusted in line with pro-forma revenue) and other gains excluding interest, tax, depreciation, amortization and Impairment expenses. Pro forma revenue is calculated as pro forma subscription revenue plus other non-recurring revenue streams such as perpetual licence fees, professional services, and one-time testing services. Pro forma subscription revenue provides a view of underlying performance by restating term licence on a recurring subscription basis (i.e. over time) plus other recurring revenues such as maintenance fees and cloud services.

3.1. STI outcomes

The executive KMP's FY25 performance measures and outcomes are summarised below.

John Ruthven				
Performance measure	Weight	Target	Achieved % of target	Payment % of target
Total Contract Value (TCV) - Pro rata for Q1	50%	\$9.7M	104%	100%
EBITDA - Pro rata for Q1	25%	(\$4.2M)	93%	0%
Cashflow - Pro rata for Q1	25%	\$3.5M	129%	100%
Total	100%			

Ian Lowe				
Performance measure	Weight	Target	Achieved % of target	Payment % of target
TCV – Collaborate ICP	10%	\$27.1M	83%	0%
Revenue churn – Collaborate ICP	5%	<10%	n/a	0%
TCV – New business Collaborate ICP	10%	\$11.7M	62%	0%
TCV – Transact & Infrastructure	25%	\$34.2M	94%	70%
Innovation in pursuit of new revenue	25%	June 30, 2025 ⁽¹⁾	100%	100%
EBITDA	12.5%	\$19.9M	80%	0%
Revenue	12.5%	\$80.3M	85%	0%
Total	100%			

Christian Shaw				
Performance measure	Weight	Target	Achieved % of target	Payment % of target
TCV – Collaborate ICP	7.5%	\$27.1M	83%	0%
Revenue churn – Collaborate ICP	5%	<10%	n/a	0%
TCV – New business Collaborate ICP	7.5%	\$11.7M	62%	0%
TCV – Transact & Infrastructure	15%	\$34.2M	94%	70%
Innovation in pursuit of new revenue	15%	June 30, 2025 ⁽¹⁾	100%	100%
EBITDA	30%	\$19.9M	80%	0%
Revenue	20%	\$80.3M	85%	0%
Total	100%			

¹Progression, validation and prototyping of new ideas.

3.2. LTI outcomes

LTI granted to John Ruthven as outgoing CEO and MD had the following active plans during FY25:

- Share Options granted under the Company's FY22 LTI plan, with a total of 655,809 Options being available for exercise with an exercise price of A\$1.98 per Option and an expiry date for all Options of 31 August 2026. All Options lapsed upon cessation of employment.
- Performance Rights granted under the Company's FY23 LTI plan, with a first-year share price hurdle of A\$0.80 and re-test features in subsequent years. All Performance Rights lapsed upon cessation of employment.

LTI granted to Ian Lowe as incoming CEO and MD had the following active plans during FY25:

- Performance Rights granted under the Company's FY25 LTI plan, with a total of 403,226 Performance Rights being available for exercise and conversion into 403,226 ordinary shares in a single tranche if a three-year service condition and a three-year share price performance condition are met. With the share price performance condition being A\$1.80, calculated using a share price VWAP for the 10 trading days following the release of the Company's FY27 earnings.

LTI granted to Christian Shaw as CFO had the following active plans during FY25:

- The first tranche of 85,470 Performance Rights, out of a total of 256,410 split across three equal annual tranches, granted under the Company's FY24 LTI plan and being available for exercise and conversion into 85,470 ordinary shares if a three-year service condition and a share price performance condition is met, were tested against the first-year share price hurdle of A\$0.80, and the hurdle was not met. However, such rights are available for re-testing against share price hurdles in subsequent years, as provided in section 2.3 above.
- Performance Rights granted under the Company's FY25 LTI plan, with a total of 241,935 Performance Rights being available for exercise and conversion into 241,935 ordinary shares in a single tranche if a three-year service condition and a three-year share price performance condition are met. With the share price performance condition being A\$1.80, calculated using a share price VWAP for the 10 trading days following the release of the Company's FY27 earnings.

3.3. Actual remuneration received in FY25

The table below reflects the actual remuneration received by the Executive KMP for the financial year ended 30 June 2025. The values presented below may differ from statutory remuneration. The statutory disclosures are prepared on an accruals basis, in accordance with the Australian Accounting Standards, including share-based payments valuation and accounting, which may not always represent what the Executive KMP have received, as some share-based payments may not manifest if certain conditions are not met.

	(AUD)	Fixed remuneration	STI	LTI	Actual total pay received
John Ruthven ¹		\$145,258	\$44,563	-	\$189,821
Ian Lowe ²		\$407,705	\$79,688	-	\$487,393
Christian Shaw		\$404,932	\$29,000	-	\$433,932

Notes

1. Ceased employment in January 2025.
2. Joined the company in October 2024.

Executive service agreements

The main terms of service agreements for Executive KMP as at 30 June 2025 are set out below.

Basis of contract	CEO and Managing Director	CFO
Contract term	No specified end date	No specified end date
Notice period	6 months by either party	6 months by either party
Termination payment in lieu of notice	6 months fixed remuneration	6 months fixed remuneration
Treatment of STI on termination	Forfeited	Forfeited
Treatment of LTI on termination	All unvested LTIs are forfeited	All unvested LTIs are forfeited

4. Non-Executive Director remuneration

4.1. Board and Committee Structure

The Board and Committees are structured as follows:

	Director	Board	Audit & Risk Committee	Nomination & Remuneration Committee	Technology & Innovation Committee
Non-Executive & Independent Directors	Peter Lloyd	✓ (Chair)	✓	✓	✓
	Kate Greenhill	✓	✓ (Chair)	✓	
	Mark Brayan	✓		✓ (Chair)	✓
	Michael Hitz	✓	✓		✓ (Chair)
Executive Director	Ian Lowe	✓			

4.2. Non-Executive Director fees

Directors' fees cover all main Board activities and committee membership. Directors can elect to salary sacrifice their fees into superannuation. Non-Executive Directors do not receive performance-related compensation or retirement benefits. The total remuneration pool for all Non-Executive Directors is not to exceed \$850,000 per annum, which the Shareholders last voted upon at the Annual General Meeting in November 2020.

There were no changes to the level or structure of Non-Executive Director (NED) fees in FY25.

Non-Executive Director fees

Board/Committee	Position	Per Position	Aggregate
Board	Fee for a Member	\$90,000	\$360,000
Board	Fee for role as Chair	\$90,000	\$90,000
Audit & Risk Committee	Fee for role as Chair	\$10,000	\$10,000
Nomination & Remuneration Committee	Fee for role as Chair	\$10,000	\$10,000
Technology & Innovation Committee	Fee for role as Chair	\$10,000	\$10,000
Total fees for Non-Executive Directors			\$480,000

5. Statutory remuneration

5.1. Directors' and Executive KMP's remuneration

Details of the nature and amount of each major element of the remuneration of each of the KMP are reported below.

For the year ended 30 June 2025 (in AUD)	<-----Short term----->		Post-employment		Long term	Share-based	Other	Proportion of remuneration		
	Salary & fees \$	Bonus \$	Non-cash benefits \$	Superannuation Contribution \$	Long service leave \$	payments Value of instruments ¹ \$	Termination Benefit \$	Total \$	Performance- related (STI)	Value of rights (LTI)
Executive KMP										
Christian Shaw	375,000	29,000	-	29,932	6,245	23,353	-	463,530	6%	5%
Directors										
Executive										
John Ruthven ²	132,650	44,563	-	12,608	-	(1,503) ⁴	176,061 ⁵	364,379	9%	0%
Ian Lowe ³	385,256	79,688	-	22,449	6,454	16,758	-	510,605	16%	3%
Non-Executive										
Peter Lloyd	161,435	-	-	18,565	-	-	-	180,000	0%	0%
Michael Hitz	89,686	-	-	10,314	-	-	-	100,000	0%	0%
Mark Brayan	89,686	-	-	10,314	-	-	-	100,000	0%	0%
Kate Greenhill	89,686	-	-	10,314	-	-	-	100,000	0%	0%
Total compensation	1,323,399	153,251	-	114,496	12,699	38,608	176,061	1,818,514		

Notes

1. The estimated value of performance rights and options are calculated at the date of grant using the Black Scholes, Binomial or Monte Carlo methodology.
2. Remuneration received up to the date the role was held.
3. Remuneration received from the date the role was held.
4. Reversal of expense for options lapsed.
5. Termination benefit includes remuneration received during Gardening leave from October 2024 to January 2025.

Remuneration Report (audited) cont.

Details of the nature and amount of each major element of the remuneration of each of the KMP are reported below.

For the year ended 30 June 2024 (in AUD)	<-----Short term----->		Post-employment	Long term	Share-based	Other	Proportion of remuneration			
	Salary & fees	Bonus	Non-cash benefits	Superannuation Contribution	Long service leave	Value of instruments ¹	Termination Benefit	Total	Performance- related (STI)	Value of rights (LTI)
	\$	\$	\$	\$	\$	\$	\$	\$		
Executive KMP										
Christian Shaw	163,333	43,750	-	13,699	2,660	7,044	-	230,486	19%	3%
Matthew Walton ²	316,471	-	-	20,549	-	-	-	337,020	0%	0%
Directors										
Executive										
John Ruthven	532,858	231,875	-	27,399	8,836	61,814	-	862,782	27%	7%
Non-Executive										
Peter Lloyd	162,162	-	-	17,838	-	-	-	180,000	0%	0%
Cathy Aston ³	67,568	-	-	7,432	-	-	-	75,000	0%	0%
Allan Brackin ³	22,523	-	-	2,477	-	-	-	25,000	0%	0%
Anne Myers ³	35,497	-	-	3,905	-	-	-	39,402	0%	0%
James Scott ³	47,297	-	-	5,203	-	-	-	52,500	0%	0%
Michael Hitz ⁴	60,743	-	-	6,682	-	-	-	67,425	0%	0%
Mark Brayan ⁴	53,333	-	-	5,867	-	-	-	59,200	0%	0%
Kate Greenhill ⁴	18,068	-	-	1,987	-	-	-	20,055	0%	0%
Total compensation	1,479,853	275,625	-	113,038	11,496	68,858	-	1,948,870		

Notes

1. The estimated value of performance rights and options are calculated at the date of grant using the Black Scholes, Binomial or Monte Carlo methodology.
2. Resigned in February 2024
2. Remuneration received up to the date the role was held.
3. Remuneration received from the date the role was held.

6. Additional statutory disclosures

6.1. Equity Instruments

All options refer to options over ordinary shares of Integrated Research Limited, which are exercisable on a one-for-one basis under the Employee Share Option Plan (ESOP). Performance rights and options granted as compensation are listed in the table below.

6.2. Analysis of performance rights and options over equity instruments granted as compensation

	Rights granted					Value yet to vest or value vested (\$)		
	Number	Date	Fair value per share (\$)	Percent vested in year	Percent lapsed in year (A)	Financial year in which grant expires	Min (B)	Max (C)
Performance Rights								
Ian Lowe	403,226	Dec-24	0.16	-	-	2027	nil	63,307
Christian Shaw	85,470	Mar-24	0.10	-	-	2026	nil	8,376
	85,470	Mar-24	0.09	-	-	2026	nil	7,692
	85,470	Mar-24	0.07	-	-	2026	nil	6,325
	241,935	Nov-24	0.21	-	-	2027	nil	50,564

Notes:

(A) The percentage lapsed in the year represents the reduction from the maximum number of performance rights available to vest due to the performance hurdles not being achieved.

(B) The minimum value of performance rights yet to vest is \$nil as the executives may not achieve the required performance hurdles or may terminate their employment prior to vesting.

(C) The maximum values presented above are based on the values calculated using the Monte Carlo methodology as applied in estimating the value of performance rights for employee benefit expense purposes.

6.3. Performance rights and options over equity instruments granted as compensation

The movement during the reporting year in the number of performance rights and options over ordinary shares in the Company held, directly, indirectly, or beneficially, by each KMP, including their related parties, is as follows:

For the year ended 30 June 2025	Held at 1 July 2024	Granted as compensation	Exercised	Other changes ¹	Held at 30 June 2025	Vested during the year	Vested and exercised at 30 June 2025
Performance Rights							
John Ruthven*	700,000	-	-	(700,000)	-	-	-
Ian Lowe	-	403,226	-	-	403,226	-	-
Christian Shaw	256,410	241,935	-	-	498,345	-	-
Options							
John Ruthven	655,809	-	-	(655,809)	-	-	-
Christian Shaw	-	-	-	-	-	-	-

¹ Other changes represent performance rights that expired or were lapsed during the year

* Employment ceased in January 2025. Performance rights and options expire on the earlier of their expiry date or termination of the individual's employment.

For the year ended 30 June 2024	Held at 1 July 2023	Granted as compensation	Exercised	Other changes ¹	Held at 30 June 2024	Vested during the year	Vested and exercised at 30 June 2024
Performance Rights							
John Ruthven	795,368	-	-	(95,368)	700,000	-	-
Christian Shaw	-	256,410	-	-	256,410	-	-
Mathew Walton	-	-	-	-	-	-	-
Options							
John Ruthven	655,809	-	-	-	655,809	218,603	-
Christian Shaw	-	-	-	-	-	-	-
Mathew Walton	-	-	-	-	-	-	-

¹ Other changes represent performance rights that expired, lapsed or were forfeited during the year

6.4. Movement in shares

The movement during the reporting period in the number of ordinary shares in the Company held, directly, indirectly, or beneficially, by each KMP, including their related parties, is as follows:

For the year ended 30 June 2025	Held at 1 July 2024	Purchases	Received on exercise of performance rights	Other changes	Sales	Held at 30 June 2025
Executive KMP						
Christian Shaw	-	-	-	-	-	-
Directors						
Executive						
John Ruthven ¹	99,593	-	-	-	-	99,593
Ian Lowe	-	-	-	-	-	-
Non-executive						
Peter Lloyd	51,263	-	-	-	-	51,263
Mark Brayan	260,000	-	-	-	-	260,000
Kate Greenhill	-	-	-	-	-	-
Michael Hitz	-	-	-	-	-	-

¹Held at 30 June 2025¹ value represents holding on last day as Key Management Personnel.

For the year ended 30 June 2024	Held at 1 July 2023	Purchases	Received on exercise of performance rights	Other changes	Sales	Held at 30 June 2024
Executive KMP						
Mathew Walton	-	-	-	-	-	-
Christian Shaw	-	-	-	-	-	-
Directors						
Executive						
John Ruthven	99,593	-	-	-	-	99,593
Non-executive						
Peter Lloyd	51,263	-	-	-	-	51,263
Mark Brayan	-	260,000	-	-	-	260,000
Kate Greenhill	-	-	-	-	-	-
Michael Hitz	-	-	-	-	-	-
Cathy Aston ¹	37,500	-	-	-	-	37,500
Allan Brackin ¹	150,000	-	-	-	-	150,000
Anne Myers ¹	21,500	-	-	-	-	21,500
James Scott ¹	74,588	-	-	-	-	74,588

¹Held at 30 June 2024¹ value represents holding on last day as Key Management Personnel.

Shareholdings at the date of the Directors' Report for existing Key Management Personnel remain unchanged.

6.5. Other Transactions with KMP

Non-Executive Director Mark Brayan provided strategic advisory services to the Company through a consultancy agreement during the reporting period. The total value of these services was \$73,750, with the services commencing in June 2024 and completed October 2024. \$42,500 was recognised as expenses in the year ended 30 June 2025.

There were no other transactions between the KMP, or their personally related entities, and the Company.

7. About this report

7.1. Basis for preparation of 2025 remuneration report

The information in this Remuneration Report has been prepared based on the requirements of the Corporations Act 2001 and applicable accounting standards. The Remuneration Report is designed to provide shareholders with a clear and detailed understanding of the Company's remuneration framework, and the link between our remuneration policies and Company performance. The Remuneration Report details the remuneration framework for the Company's KMP. This report has been audited.

7.2. Remuneration Governance

The Committee is responsible for developing the remuneration framework for IR's Executives and making recommendations related to remuneration to the Board. The Committee develops the remuneration philosophy and policies for Board approval.

The responsibilities of the Committee are outlined in their Charter, which is reviewed annually by the Board. The key responsibilities of the Committee include:

- Advising the Board on IR's policy for Executive and Director remuneration
- Making recommendations to the Board on the remuneration arrangements for Executives and Directors to ensure they are aligned with IR's vision and are set competitively to the market
- Approving KMP terms of employment

In making recommendations to the Board, the Committee reviews the appropriateness of the nature and amount of remuneration to Executives and Non-executive Directors on an annual basis. In performing its duties, the Committee can engage external advisors who are independent of Management.

Financial Report

Contents	Page
Consolidated statement of comprehensive income	36
Consolidated statement of financial position	37
Consolidated statement of changes in equity	38
Consolidated statement of cash flows	39
Notes to the Financial Report	40
1. Material accounting policies	40
2. Segment reporting	49
3. Revenue from contracts with customers	50
4. Expenditure	50
5. Other gains/(losses)	51
6. Finance income	51
7. Auditors' remuneration	51
8. Income tax	52
9. Earnings per share	52
10. Cash and cash equivalents	53
11. Trade and other receivables	53
12. Other assets	55
13. Other financial assets	55
14. Property, plant, and equipment	56
15. Deferred tax assets and liabilities	57
16. Intangible assets	58
17. Goodwill and impairment	59
18. Trade and other payables	59
19. Employee benefits	60
20. Provisions	63
21. Lease assets and liabilities	63
22. Capital and reserves	65
23. Financial instruments	66
24. Consolidated entities	68
25. Reconciliation of cash flows from operating activities	69
26. Key management personnel disclosures	69
27. Related parties	70
28. Parent entity disclosures	70
29. Subsequent events	71

Consolidated statement of comprehensive income

For the year ended 30 June 2025

In thousands of AUD	Notes	Consolidated	
		2025	2024
Revenue from contracts with customers			
Licence fees		44,601	59,132
Maintenance fees		13,213	14,304
Subscription fees		3,913	2,169
Testing solution services		2,746	3,112
Professional services		3,783	4,575
Total revenue	3	68,256	83,292
Expenditure			
Product and technology expenses		(13,514)	(12,779)
Sales, professional services and marketing expenses		(34,056)	(38,679)
General and administration expenses		(7,317)	(6,493)
Total expenditure	4	(54,887)	(57,951)
Other gains/(losses)	5	2,092	(852)
Profit before finance income and tax		15,461	24,489
Finance income	6	2,961	2,225
Profit before tax		18,422	26,714
Income tax (expense)/benefit	8	(5,064)	416
Profit for the year		13,358	27,130
Other comprehensive income			
Items that may be reclassified subsequently to profit			
Foreign exchange translation differences		798	(199)
Other comprehensive income		798	(199)
Total comprehensive income for the year		14,156	26,931
Profit attributable to:			
Members of Integrated Research		13,358	27,130
Total comprehensive income attributable to:			
Members of Integrated Research		14,156	26,931
Earnings per share attributable to members of Integrated Research:			
Basic earnings per share (cents)	9	7.56	15.57
Diluted earnings per share (cents)	9	7.43	15.18

The consolidated statement of comprehensive income is to be read in conjunction with the notes to the Financial Report set out on pages 40 to 71.

Consolidated statement of financial position

As at 30 June 2025

In thousands of AUD	Notes	Consolidated	
		2025	2024
Current assets			
Cash and cash equivalents	10	40,559	31,892
Trade and other receivables	11	40,770	41,647
Current tax assets		799	294
Other financial assets	13	143	1,110
Other current assets	12	2,605	2,959
Total current assets		84,876	77,902
Non-current assets			
Trade and other receivables	11	32,958	31,897
Other financial assets	13	491	319
Property, plant, and equipment	14	490	44
Right-of-use assets	21	1,493	241
Deferred tax assets	15	1,327	2,518
Other non-current assets	12	1,336	1,264
Total non-current assets		38,095	36,283
Total assets		122,971	114,185
Current liabilities			
Trade and other payables	18	5,709	6,069
Provisions	20	2,620	3,348
Income tax liabilities		244	258
Deferred revenue		11,542	13,921
Lease liabilities	21	718	1,341
Total current liabilities		20,833	24,937
Non-current liabilities			
Provisions	20	393	513
Lease liabilities	21	1,129	374
Total non-current liabilities		1,522	887
Total liabilities		22,355	25,824
Net assets		100,616	88,361
Equity			
Share capital	22	1,667	1,667
Reserves	22	12,370	9,981
Retained earnings		86,579	76,713
Total equity		100,616	88,361

The consolidated statement of financial position is to be read in conjunction with the notes to the Financial Report set out on pages 40 to 71.

Consolidated statement of changes in equity

For the year ended 30 June 2025

In thousands of AUD	Share capital	Translation reserve	Employee benefit reserve	Retained earnings	Total
Balance at 1 July 2024	1,667	1,671	8,310	76,713	88,361
Profit for the year	-	-	-	13,358	13,358
Other comprehensive income	-	798	-	-	798
Total comprehensive income	-	798	-	13,358	14,156
Share based payments expense	-	-	1,591	-	1,591
Dividends to shareholders	-	-	-	(3,492)	(3,492)
Balance at 30 June 2025	1,667	2,469	9,901	86,579	100,616

In thousands of AUD	Share capital	Translation reserve	Employee benefit reserve	Retained earnings	Total
Balance at 1 July 2023	1,667	1,870	6,754	49,583	59,874
Profit for the year	-	-	-	27,130	27,130
Other comprehensive income	-	(199)	-	-	(199)
Total comprehensive income	-	(199)	-	27,130	26,931
Share based payments expense	-	-	1,556	-	1,556
Balance at 30 June 2024	1,667	1,671	8,310	76,713	88,361

The consolidated statement of changes in equity is to be read in conjunction with the notes to the Financial Report set out on pages 40 to 71.

Consolidated statement of cash flows

For the year ended 30 June 2025

In thousands of AUD	Notes	Consolidated	
		2025	2024
Cash flows from operating activities			
Cash receipts from customers		66,677	72,389
Cash paid to suppliers and employees		(53,566)	(58,370)
Cash generated from operations		13,111	14,019
Income taxes paid		(4,432)	(975)
Net cash provided by operating activities	25	8,679	13,044
Cash flows from investing activities			
Payments for property, plant, and equipment		(497)	(48)
Deposit returned		1,206	-
Payment for deposit		(297)	-
Proceeds from sale of testing business		759	-
Interest received		2,948	2,321
Net cash used in investing activities		4,119	2,273
Cash flows from financing activities			
Payment of principal portion of lease liabilities		(1,404)	(1,589)
Interest payments		(101)	(96)
Payment of dividend		(3,492)	-
Net cash used in financing activities		(4,997)	(1,685)
Net increase in cash and cash equivalents		7,801	13,632
Cash and cash equivalents at 1 July		31,892	18,553
Effects of exchange rate changes on cash		866	(293)
Cash and cash equivalents at 30 June	10	40,559	31,892

The consolidated statement of cash flows is to be read in conjunction with the notes to the Financial Report set out on pages 40 to 71.

Notes to the Financial Report

For the year ended 30 June 2025

Note 1: Material accounting policies

Integrated Research Limited (the “Company”) is a company domiciled in Australia. The financial report of the Company for the year ended 30 June 2025 comprises the Company and its subsidiaries (together referred to as the “consolidated entity”).

The financial report was authorised for issue by the Directors on 26 August 2025.

Integrated Research is a for-profit Company limited by ordinary shares.

A. Statement of Compliance

The financial report is a general-purpose financial report which has been prepared in accordance with Australian Accounting Standards and Interpretations and the Corporations Act 2001. Financial Report of the consolidated entity comply with International Financial Reporting Standards and interpretations adopted by the International Accounting Standards Board.

B. Basis of Preparation

The Financial Report is presented in Australian dollars and are prepared on a going concern basis using historical cost.

The company is of a kind referred to in ASIC Legislative Instrument 2016/191 and in accordance with that Class Order, amounts in the financial report and Directors’ Report have been rounded off to the nearest thousand dollars, unless otherwise stated.

The preparation of Financial Report in conformity with Australian Accounting Standards requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income, and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. These accounting policies have been consistently applied by each entity in the consolidated entity.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.

New accounting standards and Interpretations

The accounting policies and methods of computation adopted in the preparation of the financial report are consistent with those adopted and disclosed in Integrated Research Limited's 2024 annual financial report.

The following new standards/interpretations are applicable for the first time in the current financial report:

Amendments to IAS 1: Classification of Liabilities as Current or Non-current

The amendment requires classification of liabilities as current if the entity has no right at the end of the reporting period to defer settlement for at least 12 months after the reporting period. It is assessed that the entity has no rights to defer settlement for all current liabilities in the current or past periods. There was no material impact on the financial statements.

Note 1: Material accounting policies (continued)**Standards and Interpretations issued not yet effective**

At the date of authorisation of the financial report, a number of standards and Interpretations were in issue but not yet effective.

Initial application of the following Standards is not expected to materially affect any of the amounts recognized in the Financial Report but may change the disclosures made in relation to the consolidated entity's Financial Report. The Company is still assessing the impact of all the amendments on the Company's financial statements:

Standard/Interpretation	Effective for annual reporting periods beginning on or after	Expected to be initially applied in the financial year ending
AASB 18 Presentation and Disclosure in Financial Statements	1 Jan 2027	30 June 2028
AASB 2024-2 Amendments to AASs - Classification and Measurement of Financial Instruments	1 Jan 2026	30 June 2027
AASB 2024-3 Amendments to AASs – Annual Improvements Volume II- Amendments to AASB 7	1 Jan 2026	30 June 2027
AASB 2024-3 Amendments to AASs – Annual Improvements Volume II- Amendments to AASB 9	1 Jan 2026	30 June 2027
AASB 2023-5 Amendments to AASs – Lack of Exchangeability	1 Jan 2025	30 June 2026

C. Basis of consolidation

Subsidiaries are entities controlled by the Company. Control is achieved when the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Specifically, the Company controls an investee if and only if the Company has power over the investee (i.e., existing rights that give it the current ability to direct the relevant activities of the investee). Exposure, or rights, to variable returns from its involvement with the investee, and the ability to use its power over the investee to affect its returns.

When the Company has less than a majority of the voting or similar rights of an investee, the Company considers all relevant facts and circumstances in assessing whether it has power over an investee including: the contractual arrangement with the other vote holders of the investee; rights arising from other contractual arrangements and the Company's voting rights and potential voting rights.

The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ceases when the Company loses control of the subsidiary. Assets, liabilities, income, and expenses of a subsidiary acquired or disposed of during the year are included in the statement of comprehensive income from the date the Company gains control until the date the Company ceases to control the subsidiary.

Profit or loss and each component of other comprehensive income (OCI) are attributed to the equity holders of the parent of the Company and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. When necessary, adjustments are made to the Financial Report of subsidiaries to bring their accounting policies into line with the Company's accounting policies. All intra-group assets and liabilities, equity, income, expenses, and cash flows relating to transactions between members of the Company are eliminated on consolidation.

A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. If the Company loses control over a subsidiary, it: de-recognises the assets (including goodwill) and liabilities of the subsidiary; de-recognises the carrying amount of any non-controlling interests; de-recognises the cumulative translation differences recorded in equity; recognises the fair value of the consideration received; recognises the fair value of any investment retained; recognises any surplus or deficit in profit or loss; reclassifies the parent's share of components previously recognised in OCI to profit or loss or retained earnings, as appropriate, as would be required if the Company had directly disposed of the related assets or liabilities.

Note 1: Material accounting policies (continued)

D. Foreign currency

In preparing the Financial Report of the individual entities' transactions in foreign currencies are translated at the foreign exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the year end date are translated to Australian dollars at the foreign exchange rate ruling at that date. Foreign exchange differences arising on translation are recognised in profit or loss. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Non-monetary assets and liabilities denominated in foreign currencies that are stated at fair value are translated to Australian dollars at foreign exchange rates ruling at the dates the fair value was determined.

On consolidation, the assets, and liabilities of foreign operations, including goodwill and fair value adjustments arising on consolidation are translated to Australian dollars at foreign exchange rates ruling at the year-end date. The revenues and expenses of foreign operations are translated to Australian dollars at rates approximating the foreign exchange rates ruling at the dates of the transactions. Foreign exchange differences arising on retranslation are recognised directly in other comprehensive income and accumulated in the translation reserve.

E. Property, plant, and equipment

Items of property, plant and equipment are stated at cost or deemed cost less accumulated depreciation and impairment losses (see accounting policy (M)). The cost of acquired assets includes (i) the initial estimate at the time of installation and during the period of use, when relevant, of the costs of dismantling and removing the items and restoring the site on which they are located, and (ii) changes in the measurement of existing liabilities recognised for these costs resulting from changes in the timing or outflow of resources required to settle the obligation or from changes in the discount rate.

Where parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items of property, plant, and equipment.

Depreciation is provided on property, plant, and equipment. Depreciation is calculated on a straight-line basis so as to write off the net cost of each asset over its expected useful life to its estimated residual value. Leasehold improvements are depreciated over the period of the lease or estimated useful life, whichever is the shorter, using the straight-line method. The estimated useful lives, residual values and depreciation method are reviewed annually, with the effect of any changes recognised on a prospective basis.

The following useful lives are used in the calculation of depreciation:

- Leasehold improvements 6 to 10 years
- Plant and equipment 4 to 8 years

F. Leases

The Company assesses at contract inception whether a contract is, or contains, a lease. The Company applies a single recognition and measurement approach for all leases, except for short-term leases and low-value assets. The Company recognises lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

Right-of-use assets

The right-of-use assets comprise the initial measurement of the corresponding lease liability, lease payments made at or before the commencement day, less any lease incentives received and any initial direct costs. They are subsequently measured at cost less accumulated depreciation and impairment losses. Right-of-use assets are depreciated on a straight-line basis over the lease term.

Note 1: Material accounting policies (continued)

Lease liabilities

At the commencement date of the lease, the Company recognises lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating a lease, if the lease term reflects the Company exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognised as expense in the period on which the event or condition that triggers the payment occurs.

In calculating the present value of lease payments, the Company uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset.

G. Intangible Assets

Research and development

Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognised in profit or loss as incurred.

Expenditure on development activities, whereby research findings are applied to a plan or design for the production of new or substantially improved products and processes, is capitalised if the product or process is technically and commercially feasible and the consolidated entity has sufficient resources to complete development.

The useful lives of the capitalised assets are assessed as finite. The expenditure capitalised includes the cost of materials, direct labour, and an appropriate proportion of overheads. Other development expenditure is recognised in profit or loss as an expense as incurred.

Capitalised development expenditure is stated at cost less accumulated amortisation and impairment losses (see accounting policy (I)).

Amortisation is charged to profit or loss on a straight-line basis over the estimated useful life, but no more than three years, the exception being for the Company's next generation Prognosis Cloud platform which is amortised over five years.

Intellectual property

Intellectual property acquired from third parties is amortised over its estimated useful life, but no more than three years.

Computer software

Computer software is stated at cost and amortised on a straight-line basis over a two and a half to three-year period. SaaS arrangements are service contracts providing the Company with the right to access the cloud provider's application software over the contract period. Costs incurred to configure or customise, and the ongoing fees to obtain access to the cloud provider's application software, are recognised as operating expenses when the services are received.

Note 1: Material accounting policies (continued)

H. Trade and other receivables

Trade and other receivables are stated at their amortised cost less expected credit losses. To measure the expected credit losses the Company utilises the simplified approach in calculating the expected credit loss and recognises a loss allowance based on a lifetime expected credit losses at each reporting date. The Company has established a provision matrix calculated based on the group historical credit loss experience adjusted for forward-looking factors.

Trade receivables are written off when there is no reasonable expectation of recovery.

For the trade receivables with extended payment terms beyond twelve months, the receivable is initially recognised at fair value less transaction costs calculated by applying a discount to the contracted cash flows. The discount rate applied is based upon the corporate borrowing rate that would apply to the type of customer, considering the customers' credit worthiness based on its size and jurisdiction.

I. Cash and cash equivalents

Cash and cash equivalents comprise cash balances and call deposits with an original maturity of three months or less.

J. Impairment

The carrying amounts of the consolidated entity's assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, the asset's recoverable amount is estimated.

For intangible assets that are not yet available for use, the recoverable amount is estimated at each year end date.

An impairment loss is recognised whenever the carrying amount of an asset or its cash generating unit exceeds its recoverable amount. Impairment losses are recognised in profit or loss unless the asset has previously been revalued, in which case the impairment loss is recognised as a reversal to the extent of that previous revaluation with any excess recognised through profit or loss.

A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years.

The recoverable amount of other assets is the greater of their fair value less costs to sell and value in use.

In assessing recoverable value, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and their risk specific to the asset. For an asset that does not generate largely independent cash inflows, the recoverable amount is determined for the cash-generating unit to which the asset belongs.

K. Employee benefits

Superannuation

Obligations for contributions to defined contribution pension plans are recognised as an expense in profit or loss as incurred. There are no defined benefit plans in operation.

Long-term service benefits

The consolidated entity's net obligation in respect of long-term service benefits, other than pension plans, is the amount of future benefit that employees have earned in return for their service in the current and prior periods. The obligation is calculated using expected future increases in wage and salary rates including related on-costs and expected settlement dates, and is discounted using the rates attached to the high quality corporate bond rate at the year-end date which have maturity dates approximating to the terms of the consolidated entity's obligations.

Note 1: Material accounting policies (continued)

Share-based payment transactions

The performance rights and options programmes allow the consolidated entity's employees to acquire shares of the Company. The fair value of performance rights and options granted are recognised as an employee expense with a corresponding increase in equity. The fair value is measured at grant date and spread over the period during which the employees become unconditionally entitled to the performance rights or options. The fair value of the instrument granted is measured using a Black-Scholes, Binomial or Monte-Carlo methodology, considering the terms and conditions upon which the options were granted. The amount recognised as an expense is adjusted to reflect the actual number of share options or performance rights that are expected to vest.

Wages, salaries, annual leave, and non-monetary benefits

Liabilities for employee benefits for wages, salaries and annual leave represent present obligations resulting from employees' services provided to the year-end date, calculated at undiscounted amounts based on remuneration wage and salary rates that the consolidated entity expects to pay as at the year-end date.

L. Provisions

A provision is recognised in the statement of financial position when the consolidated entity has a present legal or constructive obligation as a result of a past event, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and, where appropriate, the risks specific to the liability.

Employee benefits

Provisions for employee benefits include liabilities for annual leave and long service leave and are measured at the amounts expected to be paid when the liabilities are settled.

Make good

The make good provision is for leases undertaken by the Company. For each provision raised a corresponding asset has been recognised and is amortised over the shorter of the term of the lease or the useful life of the asset.

M. Trade and other payables

Trade and other payables are stated at their amortised cost.

N. Revenue

Revenue from contracts with customers is recognised either at a point in time (licence fees) or over-time (maintenance, SaaS, testing solutions and professional services fees), regardless of when payment is received. Amounts disclosed as revenue are net of agency commissions and discounts. Where the Company bundles the products or services, the transaction price is allocated to each performance obligation based on the proportionate stand-alone selling prices.

Licence fees are recognised on delivery of the licence key, where the Company's contracts with customers provide the right to use the Company's intellectual property. As such, the Company's performance obligation is satisfied at the point in time which the customer receives the licence key.

Maintenance fees are recognised on a monthly basis over the term of the service agreement, which may range between one to five years. Services provided to customers under maintenance contracts include technical support and supply of software upgrades.

Subscription fees are recognised on a monthly basis over the term of the service agreement, which may range between one to five years. The Company's contracts with customers provide a right of access to the Company's intellectual property (hosted on the Company's cloud environment) for the duration of the term of the contract.

Testing solutions services revenues are recognised either ratably over a service period or as services are rendered. Testing services relate to the provision of services to performing testing of customer environments.

Note 1: Material accounting policies (continued)

Professional services are revenues recognised as the services are rendered, typically in accordance with the achievement of contract milestones or hours expended. Professional services include implementation and configuration services for licenced software.

Unsatisfied performance obligations are disclosed as deferred revenue on the consolidated statement of financial position. Where the Company has a multi-year non-cancellable contractual commitment but does not expect to satisfy the performance obligation within twelve months, no deferred revenue or trade receivable is recognised.

The Company typically provides multi-year payment terms to customers ranging between one to five years. For such contracts with customers, the transaction price is discounted using a rate that would be reflected in a separate financing transaction between the Company and the customer. This amount is recognised ratably as finance income over the payment period.

Directly related contract costs in obtaining the customer contracts are expensed unless they are incremental to obtaining the contract and the Company expects to recover those costs. These costs are recognised as contract assets and amortised over the life of the contract they relate to. The incremental costs in obtaining customer contracts for the Company relate to specified commissions paid to employees which meet the criteria of directly related contract costs.

No revenue is recognised if there are significant uncertainties regarding the recovery of the transaction price, the costs incurred or to be incurred cannot be measured reliably or there is a risk of return.

O. Financing income

Financing income comprises interest receivable on funds invested and the financing component of the sale of licences, less interest payable on borrowings.

P. Income tax

Income tax on the profit or loss for the periods presented comprises current and deferred tax. Income tax is recognised in profit or loss except to the extent that it relates to items recognised directly in equity, in which case it is recognised in equity.

Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at the year-end date, and any adjustment to tax payable in respect of previous years.

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The amount of deferred tax provided is based on the expected manner of realisation or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the year-end date.

A deferred tax asset is recognised only to the extent that it is probable that future taxable profits will be available against which the asset can be utilised. Deferred tax assets are reduced to the extent that it is no longer probable that the related tax benefit will be realised.

Additional dividend franking deficit tax that arises from the distribution of dividends are recognised at the same time as the liability to pay the related dividend.

Q. Goods and Services Tax

Revenue, expenses, and assets are recognised net of the amount of goods and services tax (GST), or similar taxes, except where the amount of GST incurred is not recoverable from the taxation authority. In these circumstances, the GST is recognised as part of the cost of acquisition of the asset or as part of the expense.

Receivables and payables are stated with the amount of GST included. The net amount of GST recoverable or payable is included as a current asset or liability in the statement of financial position.

Cash flows are included in the statement of cash flows on a gross basis. The GST components of cash flows arising from investing and financing activities, which are recoverable or payable are classified as operating cash flows.

Note 1: Material accounting policies (continued)

R. Business Combination and Goodwill

Business combinations are accounted for using the acquisition method. The cost of an acquisition is measured as the aggregate of the consideration transferred at acquisition date measured at fair value. Any contingent consideration to be transferred by the acquirer will be recognised at fair value at the acquisition date. Changes in the fair value of the contingent consideration are recognised in the Statement of Comprehensive Income.

Goodwill is initially measured at cost, being the excess of the aggregate of the consideration transferred over the net identifiable assets acquired and liabilities assumed. Goodwill is tested annually for impairment. Acquisition-related costs are expensed as incurred and included in administrative expenses.

S. Significant accounting judgements, estimates and assumptions

The carrying amounts of certain assets and liabilities are often determined based on estimates and assumptions of future events. The key estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of certain assets and liabilities within the next annual reporting period are:

Revenue Recognition - Multi-element contracts or agreements

The majority of the Company's sales contracts involve multiple-element arrangements, for example a single software sales transaction that combines the delivery of a software licence and rendering of maintenance and other professional services.

Revenue recognition for multiple-element arrangements has inherent complexities due to the judgment required to properly allocate the revenue amongst respective contracted activities.

Intangible assets - Development

An intangible asset arising from development expenditure on an internal project is recognised only when the consolidated entity can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the development and the ability to measure reliably the expenditure attributable to the intangible asset during its development. Following the initial recognition of the development expenditure, the cost model is applied requiring the asset to be carried at cost less any accumulated amortisation and accumulated impairment losses. Any expenditure capitalised is amortised over the period of expected benefits from the related project commencing from the commercial release of the project. The carrying value of an intangible asset arising from development expenditure is tested for impairment annually when the asset is not yet available for use or more frequently when an indication of impairment arises during the reporting period.

Share based payment transactions

The consolidated entity measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by using either a Black-Scholes or Monte Carlo methodology and applying management determined probability factors relating to non-market vesting conditions.

Provision for expected credit losses of trade and other receivables

The Company uses a provision matrix to calculate the expected credit loss for trade and other receivables. The provision rates are based on the days overdue and differ by geography. The provision matrix is based on the historical default experience for the Company and adjusted for forward-looking information and includes the use of macroeconomic information where appropriate. The determination of the provision rates is considered a significant estimate as it is sensitive to change in circumstances and of forecast of economic conditions. The expected credit loss also may not be representative of the customers' actual default in the future.

Note 1: Material accounting policies (continued)

Income Tax

The Company regularly assesses the adequacy of income tax provisions having regard to the differing tax rules and regulations applicable in the various jurisdictions in which the Company operates. Due to the complexities of tax rules and regulations in numerous jurisdictions, matters such as the availability and timing of tax deductions and the application of the arm's length principle to cross-border transactions often require significant judgements and assumptions to be made. Deferred tax assets are recognised for deductible temporary differences and tax losses to the extent that it is probable that future taxable profits will be available to utilise those temporary differences and tax losses. Significant judgement is required by the Company to determine the amount of deferred tax assets that can be recognised, based upon the likely timing and the level of future taxable profits.

For personal use only

Note 2. Segment reporting

The Chief Operating Decision Maker (CODM), being the Chief Executive Officer, reviews a variety of information, including profit, on the performance of Prognosis solution across the group for the purpose of resource allocation.

The principal geographical regions are the Americas – Operating from the United States with responsibility for the countries in North, Central and South America, Europe – operating from the United Kingdom and Germany with responsibility for the countries in Europe, Asia Pacific – operating from Australia and Singapore with responsibility for the countries in the rest of the world, and Corporate Australia – with responsibility for research and development and corporate head office functions of the Company. Inter-segment pricing is determined on an arm's length basis.

Information regarding these geographic regions is presented below.

In thousands of AUD	Americas		Europe		Asia Pacific		Corporate Australia ¹		Eliminations		Consolidated	
	2025	2024	2025	2024	2025	2024	2025	2024	2025	2024	2025	2024
Sales to customers outside the consolidated entity	48,092	59,545	4,693	7,917	15,471	15,830	-	-	-	-	68,256	83,292
Inter-region revenue	-	-	-	-	-	-	34,322	46,920	(34,322)	(46,920)	-	-
Total regional revenue	48,092	59,545	4,693	7,917	15,471	15,830	34,322	46,920	(34,322)	(46,920)	68,256	83,292

In thousands of local currencies	Americas (USD)		Europe (GBP)	
	2025	2024	2025	2024
Sales to customers outside the consolidated entity	30,884	39,138	2,358	4,128
Inter-region sales	-	-	-	-
Total regional revenue	30,884	39,138	2,358	4,128

¹ Corporate Australia includes both the research and development and corporate head office functions of Integrated Research Limited.

Note 3. Revenue from contracts with customers

Information regarding the disaggregation of the Company's revenues from contracts with customers is presented below.

In thousands of AUD	Consolidated	
	2025	2024
Timing of Revenue Recognition:		
At a point in time	44,601	59,132
Over time	23,655	24,160
Total Revenue from contracts with customers	68,256	83,292
Type of product Group		
Collaborate	33,023	35,154
Infrastructure	18,170	25,129
Transact	13,280	18,434
Professional services	3,783	4,575
Total Revenue	68,256	83,292

The transaction price allocated to the remaining performance obligations (unsatisfied or partially unsatisfied), which are not included above, is \$20,492,000 (2024: \$19,089,000) as at 30 June and is expected to be recognised as revenue in two to five years. This amount relates to contracts with customers where the Company has a multi-year non-cancellable contractual commitment but does not expect to satisfy the performance obligation within twelve months, and no deferred revenue or trade receivable is recognised.

Note 4. Expenditure

Total expenditure of \$54,887,000 (2024: 57,951,000) includes:

In thousands of AUD	Note	Consolidated	
		2025	2024
Employee benefits expense:			
Defined contribution plans		1,882	2,060
Equity settled share-based payments		1,591	1,556
Other employee benefits		37,067	39,367
		40,540	42,983
Depreciation and amortization		421	112
Expected credit loss provision expense / (gain)	11	144	(182)

Note 5. Other gains/(losses)

In thousands of AUD	Note	Consolidated	
		2025	2024
Currency exchange gains/(losses)		523	(940)
Gain on sale of testing solution business		1,218	-
Other income		351	88
		2,092	(852)

As part of the sale of the non-core testing solution business, liabilities with a net book value of \$401,000 were disposed by the Company during the year (2024: nil), resulting in a net gain on sale of \$1,218,000 (2024: Nil). During the year, the company received sale consideration of \$759,000.

Note 6. Finance income

In thousands of AUD	Consolidated	
	2025	2024
Interest income	3,062	2,321
Interest on lease liability	(101)	(96)
	2,961	2,225

Note 7. Auditors' remuneration

In AUD	Consolidated	
	2025	2024
Fees to Ernst & Young (Australia)		
Fees for auditing the consolidated financial report of the Company and auditing the statutory financial reports of any controlled entities	330,321	323,450
Total auditor's remuneration	330,321	323,450

Note 8. Income tax

Recognised in profit for the year

In thousands of AUD	Note	Consolidated	
		2025	2024
Current income tax:			
Current income tax expense		3,556	855
Adjustments in respect of current income tax of previous year		317	(297)
		3,873	558
Deferred tax:			
Relating to origination and reversal of temporary differences	15	1,191	6,568
Recognition of previously unrecognised deferred taxes	15	-	(7,542)
		1,191	(974)
Total income tax expense / (benefit) in profit and loss		5,064	(416)

Numerical reconciliation between income tax benefit and profit before tax

In thousands of AUD	Consolidated	
	2025	2024
Profit before tax	18,422	26,714
Income tax using the domestic corporate tax rate of 30%	5,527	8,014
Increase in income tax expense due to:		
Non-deductible expenses	395	463
Adjustments in respect of current income tax of previous year	317	(297)
Decrease in income tax expense due to:		
R&D tax incentive	(923)	(974)
Recognition of previously unrecognised deferred taxes	-	(7,542)
Effect of tax rates in foreign jurisdictions	(252)	(80)
Income tax expense / (benefit)	5,064	(416)

Note 9. Earnings per share

The calculation of basic and diluted earnings per share at 30 June 2025 was based on the profit attributable to ordinary shareholders of \$13,358,000 (2024: \$27,130,000); a weighted number of ordinary shares outstanding during the year ended 30 June 2025 of 176,757,152 (2024: 174,281,213); and a weighted number of ordinary shares (diluted) outstanding during the year ended 30 June 2025 of 179,830,031 (2024: 178,761,286), calculated as follows:

In thousands of AUD	Consolidated	
	2025	2024
Profit for the year	13,358	27,130

Note 9. Earnings per share (continued)

Weighted average number of shares used as the denominator

Number	Consolidated	
	2025	2024
Number for basic earnings per share:		
Ordinary shares	176,757,152	174,281,213
Effect of employee share plans on issue	3,072,879	4,480,073
Number for diluted earnings per share	179,830,031	178,761,286
Basic earnings per share (cents)	7.56	15.57
Diluted earnings per share (cents)	7.43	15.18

Note 10. Cash and cash equivalents

In thousands of AUD	Consolidated	
	2025	2024
Cash at bank	7,896	19,892
Short term deposits	32,663	12,000
	40,559	31,892

Cash at banks earns interest at floating rates based on daily bank deposit rates. Short-term deposits are made for varying periods of between one day and three months, depending on the immediate cash requirements of the Group, and earn interest at the respective short-term deposit rates.

Note 11. Trade and other receivables

Current

In thousands of AUD	Consolidated	
	2025	2024
Trade receivables	40,880	41,377
Less: Allowance for expected credit losses	(186)	(58)
	40,694	41,319
GST receivable	76	328
	40,770	41,647

Note 11. Trade and other receivables (continued)

Non-current

In thousands of AUD	Consolidated	
	2025	2024
Trade receivables	32,958	31,897

The Company provides customers with good credit worthiness with extended payment plans over the committed term of the licence contract ranging between one to five years. For customers not on extended payment plans the credit period on sales ranges from 30 to 90 days.

Ageing of past due but not impaired:

In thousands of AUD	Note	Consolidated	
		2025	2024
Past due 30 days		500	771
Past due 60 days		120	935
Past due 90 days		217	140
Total	23	837	1,846

The movement in the allowance for expected credit losses in respect of trade receivables is detailed below:

In thousands of AUD	Consolidated	
	2025	2024
Balance at beginning of year	58	301
Amounts written back during the year	(16)	(61)
Increase/(decrease) in provision	144	(182)
Balance end of year	186	58

The Company has used the following criteria to assess the allowance loss for expected credit losses shown above:

- historical default experience. Loss rate for 2025 was 0.14% (2024: 0.21%);
- macroeconomic factors specific to the geography of the customer;
- an individual account by account specific risk assessment based on past credit history; and
- any prior knowledge of debtor insolvency or other credit risk.

Included in the Company's trade receivable balance are debtors which are 90 days past due at the reporting date which the Company has not provided for as there has been no significant change in credit quality and the consolidated entity believes that the amounts are still recoverable.

Note 12. Other assets

Current

In thousands of AUD	Consolidated	
	2025	2024
Prepayments	1,621	1,906
Contract assets	984	1,053
Total	2,605	2,959

Non-current

In thousands of AUD	Consolidated	
	2025	2024
Contract assets	1,336	1,264
Total	1,336	1,264

The Company pays sales commission to its employees for certain contracts; these costs are recognized as costs incurred to obtain a contract and included as contract assets.

Note 13. Other financial assets

Current

In thousands of AUD	Consolidated	
	2025	2024
Deposits	29	1,110
Interest receivable	114	-
Total	143	1,110

Deposits include deposits for rental premises due to expire in February 2026.

Non-current

In thousands of AUD	Consolidated	
	2025	2024
Deposits	491	319

Deposits include bank deposit for a cash backed guarantee for rental premises. The carrying amount of other financial assets is a reasonable approximation of their fair value.

Note 14. Property, plant and equipment

Plant and equipment	Consolidated	
	2025	2024
In thousands of AUD		
At cost	545	6,007
Accumulated depreciation and impairment	(84)	(5,963)
	461	44

Leasehold improvements	Consolidated	
	2025	2024
In thousands of AUD		
At cost	32	3,117
Accumulated depreciation and impairment	(3)	(3,117)
	29	-

Total property, plant, and equipment	Consolidated	
	2025	2024
In thousands of AUD		
At cost	577	9,124
Accumulated depreciation and impairment	(87)	(9,080)
	490	44

Plant and Equipment	Consolidated	
	2025	2024
In thousands of AUD		
Carrying amount at start of year	44	-
Additions	497	48
Effects of foreign currency exchange	-	-
Depreciation expense	(80)	(4)
Carrying amount at end of year	461	44

Leasehold Improvements	Consolidated	
	2025	2024
In thousands of AUD		
Carrying amount at start of year	-	-
Additions	32	-
Depreciation expense	(3)	-
Carrying amount at end of year	29	-

During the year, the Group has written off certain assets included in the Leasehold Improvements and Plant and Equipment that were already fully written off and are not in use anymore.

For personal use only

Note 15. Deferred tax assets and liabilities

Deferred tax assets and liabilities are attributable to the following:

Consolidated In thousands of AUD	Assets		Liabilities		Net	
	2025	2024	2025	2024	2025	2024
Right-of-use assets	-	-	(407)	-	(407)	-
Property, plant, and equipment	35	131	-	-	35	131
Deferred commission	-	-	(447)	(435)	(447)	(435)
Share based payments	187	198	-	-	187	198
Trade and other payables	312	228	-	-	312	228
Lease Liability	497	405	-	-	497	405
Deferred Revenue	883	807	-	-	883	807
Provisions	710	992	-	-	710	992
Unrealized foreign exchange gain	-	193	(412)	-	(412)	193
Others	-	-	(31)	(1)	(31)	(1)
Deferred tax assets/(liabilities)	2,624	2,954	(1,297)	(436)	1,327	2,518
Set off of deferred tax liabilities	(1,297)	(436)	1,297	436	-	-
Net deferred tax assets/(liabilities)	1,327	2,518	-	-	1,327	2,518

Movement in temporary differences during the year:

For year ended 30 June 2025 In thousands of AUD	Consolidated			
	Balance 1 July 2024	Recognised in expense	Recognised in equity	Balance 30 June 2025
Right-of-use assets	-	(407)	-	(407)
Property, plant, and equipment	131	(96)	-	35
Deferred commission	(435)	(12)	-	(447)
Share based payments	198	(11)	-	187
Trade and other payables	228	84	-	312
Lease Liability	405	92	-	497
Deferred Revenue	807	76	-	883
Provisions	992	(282)	-	710
Unrealized foreign exchange gain	193	(605)	-	(412)
Others	(1)	(30)	-	(31)
	2,518	(1,191)	-	1,327

Note 15. Deferred tax assets and liabilities (continued)

For year ended 30 June 2024 In thousands of AUD	Consolidated			Balance 30 June 2024
	Balance 1 July 2023	Recognised in income	Recognised in equity	
Property, plant, and equipment	-	131	-	131
Trade and other payables	342	(114)	-	228
Deferred commission	210	(645)	-	(435)
Share based payments	165	33	-	198
Lease Liability	864	(459)	-	405
Provisions	776	216	-	992
Deferred Revenue	1,123	(316)	-	807
Unrealized foreign exchange gain	(538)	731	-	193
Other	-	(1)	-	(1)
Losses and R&D credits ¹ available for offset against future taxable income	8,085	(8,085)	-	-
De-recognition of deferred tax	(9,518)	9,518	-	-
	1,509	1,009	-	2,518

¹ R&D Credits refer to tax incentive received for conduction eligible R&D activities under the Research and Development Tax Incentive (R&DTI) scheme administered jointly by AusIndustry and Australian Taxation Office. These tax Incentives can be used by the company to offset its future tax liability.

² As at 30 June 2024, the Company had no un-recognised deferred tax assets related to Australian R&D tax incentives (30 June 2023: \$8.1 million) and no unrecognized deferred tax assets on temporary differences (30 June 2023: \$1.4 million).

Note 16. Intangible assets

The balance of capitalized intangible assets comprises:

Cost	Software development	Third party software	Goodwill	Total
In thousands of AUD				
Balance at 1 July 2023	62,127	2,288	3,727	68,142
Fully amortised & offset	-	-	-	-
Effects of foreign currency exchange	-	-	-	-
Balance at 30 June 2024	62,127	2,288	3,727	68,142

In thousands of AUD	Software development	Third party software	Goodwill	Total
Balance at 1 July 2024	62,127	2,288	3,727	68,142
Fully amortised & offset	-	-	-	-
Effects of foreign currency exchange	-	-	-	-
Balance at 30 June 2025	62,127	2,288	3,727	68,142

Note 16. Intangible assets (continued)

Accumulated Amortisation

In thousands of AUD	Software development	Third party software	Goodwill	Total
Balance at 1 July 2023	62,127	2,288	3,727	68,142
Fully amortised & offset	-	-	-	-
Amortisation for year	-	-	-	-
Impairment	-	-	-	-
Balance at 30 June 2024	62,127	2,288	3,727	68,142

Balance at 1 July 2024	62,127	2,288	3,727	68,142
Fully amortised & offset	-	-	-	-
Amortisation for year	-	-	-	-
Impairment	-	-	-	-
Balance at 30 June 2025	62,127	2,288	3,727	68,142

Carrying amounts

In thousands of AUD	Software development	Third party software	Goodwill	Total
Balance at 30 June 2024	-	-	-	-
Balance at 30 June 2025	-	-	-	-

Note 17. Asset impairment

Management has identified the Group as having one cash generating unit (the Prognosis CGU).

In the current year, as at 30 June 2025, the Group has not identified any indicators which suggest reversal of asset impairment recognised in prior years. There has been no material change in the key assumptions used to determine the recoverable amount of the cash generating unit.

Note 18. Trade and other payables

In thousands of AUD	Consolidated	
	2025	2024
Trade and other payables	5,709	6,069

The average credit period on trade and other payables is 30 days.

Note 19. Employee benefits

Current

In thousands of AUD	Consolidated	
	2025	2024
Liability for annual leave	1,669	1,693
Liability for long service leave	951	955
	2,620	2,648

Non-current

In thousands of AUD	Consolidated	
	2025	2024
Liability for long service leave	265	485
Accrued commission	62	-
	327	485

Pension plans

Employees of the consolidated entity accumulate pension benefits through statutory contributions by the entities in the consolidated entity as required by the laws of the jurisdictions in which they operate, supplemented by individual contributions.

Share based payments

Employee Equity Plan

In April 2023, the consolidated entity established the Integrated Research Limited Equity Plan Rules (Plan), which replaced the prior plan rules adopted in 2011. The Plan enables the Company to offer eligible employees the right to obtain shares in Integrated Research at no cost contingent upon performance conditions being met (otherwise referred to as performance rights).

The annual long term incentive (LTI) equity allocations are broadly broken into two groups: grants to Company staff (Staff LTI), and grants to Company executives (Executive LTI). The performance conditions include a service period with performance components. The performance rights are automatically exercised into shares upon the service and performance conditions being met. Allocations for Staff LTI vest annually over a three year period, so long as the recipient remains employed at the vesting date and receives a "meets expectations" performance rating in the prior year. Executive LTI equity grants vest over a three year period with performance hurdles tied to company performance, the details of the FY25 Executive LTI performance hurdles are provided in the Remuneration Report.

During the year ended 30 June 2025, the consolidated entity recognised an expense through statement of Comprehensive Income of \$1,591,000 related to the fair value of rights and options (2024: \$1,556,000).

There were no cancellations or modifications to the awards in 2025 or 2024.

Note 19. Employee benefits (continued)

Movements during the year

The following tables provide the movement in performance rights and options and weighted average exercise prices (WAEP) during the year:

	2025	2025	2024	2024
Performance Rights	Staff LTI	Executive LTI	Staff LTI	Executive LTI
In thousands of instruments				
Outstanding at the beginning of the year	7,359	3,494	5,216	1,684
Granted during the year	3,151	1,675	5,432	1,905
Forfeited during the year	(1,185)	(2,288)	(1,761)	(95)
Vested during the year	(2,744) ¹	-	(1,528) ²	-
Outstanding at the end of the year	6,581	2,881	7,359	3,494
Exercisable at the end of the year (vested)	-	-	-	-

¹ Weighted average share price of exercised performance rights for the period was \$0.616

² Weighted average share price of exercised performance rights for the period was \$0.350

The weighted average remaining contractual life for the performance rights outstanding as at 30 June 2025 was 1.09 years (2024: 1.69 years).

The weighted average fair value of performance rights under the Staff LTI allocation granted during the year was \$0.71 (2024: \$0.34).

The weighted average fair value of performance rights under the Executive LTI allocation granted during the year was \$0.20 (2024: \$0.065).

The exercise price for the performance rights at the end of the year was nil (2024: nil).

	2025	2025	2024	2024
Options	Number	WAEP	Number	WAEP
In thousands of instruments				
Outstanding at the beginning of the year	1,147	\$1.98	1,147	\$1.98
Granted during the year	-	-	-	-
Forfeited during the year	(926)	\$1.98	-	-
Exercised during the year	-	-	-	-
Outstanding at the end of the year	221	\$1.98	1,147	\$1.98
Exercisable at the end of the year (vested)	221	\$1.98	765	\$1.98

The weighted average remaining contractual life for the share options outstanding as at 30 June 2025 was 1.17 years (2024: 2.17 years).

The exercise price for options outstanding at the end of the year was \$1.98 (2024: \$1.98).

Note 19. Employee benefits (continued)**Inputs on instruments granted**

The following tables list the inputs to the models use for the Employee Equity plans for the years ended 30 June 2025 and 2024:

For the year ended 30 June 2025	Staff LTI	Executive LTI
Weighted average fair values at measurement date	\$0.71	\$0.20
Expected dividends	2.68%	3.33%-3.81%
Expected volatility	72.46%-72.59%	72.46%-72.59%
Risk-free interest rate	3.33%-3.84%	3.33%-3.84%
Contractual life (expressed in years)	2.93	2.73-2.76
Weighted average share price	\$0.75	\$0.58
Exercise price	Nil	Nil
Performance hurdles - IRI share price at testing date	N/A	\$1.80
Testing date	N/A	Aug-27
Model Used	Black Scholes	Monte Carlo

For the year ended 30 June 2024	Staff LTI	Executive LTI
Weighted average fair values at measurement date	\$0.34	\$0.065
Expected dividends	0.0%	0.0%
Expected volatility	64.74%	64.74%
Risk-free interest rate	3.97%	3.97%
Contractual life (expressed in years)	2.84	2.71
Weighted average share price	\$0.34	\$0.31
Exercise price	Nil	Nil
Performance hurdles - IRI share price at testing date	N/A	\$0.80 (T1), \$1.20 (T2), \$1.60 (T3)
Testing date	N/A	Aug-24 (T1), Aug-25 (T2), Aug-26 (T3)
Model Used	Black Scholes	Monte Carlo

The fair value of services received in return for performance rights and options granted to employees is measured by reference to the fair value of rights granted.

Note 20. Provisions

Current

In thousands of AUD	Note	Consolidated	
		2025	2024
Employee benefits	19	2,620	2,648
Lease make good		-	700
		2,620	3,348

The Company paid \$499,500 related to the make good obligations of the old North Sydney office premises. The remainder of the lease make good provision was released to the Profit or Loss statement and is included in General and administration expenses.

Non-current

In thousands of AUD	Note	Consolidated	
		2025	2024
Employee benefits	19	327	485
Lease make good		66	28
		393	513

Note 21. Lease assets and liabilities

The Company has lease contracts for office space and equipment used in operations, with terms ranging from 1 to 5 years. The company's obligations under its leases are secured by the lessor's title to the leased assets.

During the year, the company exited the lease for the North Sydney office premises and entered into a new lease contract in Sydney CBD for four years. The company recognised a right-of-use asset of \$1,572,000, lease liability of \$1,536,000 and make good provision of \$36,000. The incremental borrowing rate assumed for the new lease was 7.0%.

The lease liabilities were discounted at the incremental borrowing rates as at inception of the respective lease. The incremental borrowing rates for the portfolio of leases were between 3% and 7%. Finance income decreased by \$101,000 (2024: \$96,000) relating to the interest expense on lease liabilities recognised.

Right-of-use assets

Office premises	In thousands of AUD	Consolidated	
		2025	2024
At cost		1,949	8,329
Accumulated depreciation and impairment		(456)	(8,088)
		1,493	241

Note 21. Lease assets and liabilities (continued)

Office premises	Consolidated	
	2025	2024
In thousands of AUD		
Carrying amount at start of year	241	-
Additions	1,572	352
Effects of foreign currency exchange	18	(3)
Depreciation expense	(338)	(108)
Carrying amount at end of year	1,493	241

Current lease liabilities

	Consolidated	
	2025	2024
In thousands of AUD		
Lease liabilities	718	1,341
	718	1,341

Non-current lease liabilities

	Consolidated	
	2025	2024
In thousands of AUD		
Lease liabilities	1,129	374
	1,129	374

Contractual undiscounted cash outflows used to calculate lease liability

	Consolidated	
	2025	2024
In thousands of AUD		
Less than one year	816	1,379
Between one and five years	1,234	396
	2,050	1,775

Note 22. Capital and reserves

Share capital

In thousands of shares	Ordinary shares	
	2025	2024
On issue 1 July	174,609	173,081
Issued against employee performance right exercised	2,744	1,528
On issue 30 June	177,353	174,609

The company does not have authorized capital or par value in respect of its issued shares.

The holders of ordinary shares are entitled to receive dividends as declared from time to time and are entitled to one vote per share at meetings of the Company. All shares rank equally with regard to the Company's residual assets.

Translation reserve

The translation reserve comprises all foreign exchange differences arising from the translation of the Financial Report of foreign operations where their functional currency is different to the presentation currency of the consolidated entity, as well as from the translation of liabilities that hedge the consolidated entity's net investment in a foreign subsidiary.

Employee benefit reserve

The employee benefit reserve arises on the grant of either share options or performance rights to employees under the Integrated Research Limited Equity Plan Rules (adopted in April 2024) or the Integrated Research Performance Rights and Option Plan (adopted in November 2011). Refer to note 19 for further details.

Dividends

Dividends paid during the year

During the financial year ended 30 June 2025, the Company paid the following dividends on fully paid ordinary shares:

In thousands of AUD	Cents per share	Total amount	Franked/ unfranked	Record Date	Date of payment
Final dividend for the year ended 30 June 2024	2.00	3,492	100% franked	03 September 2024	15 October 2024

Dividends declared subsequent to reporting date

On 26 August 2025, the Directors declared a fully franked final dividend for the year ended 30 June 2025 of 2.0 cents per ordinary share and will be paid on 21 October 2025 with a record date of 04 September 2025. The final dividend to be paid in October 2025 has not been recognised as a liability in the financial statements as at 30 June 2025.

In thousands of AUD	Cents per share	Total amount	Franked/ unfranked	Record Date	Date of payment
Final dividend declared for the year ended 30 June 2025	2.00	3,547	100% franked	04 September 2025	21 October 2025

Franking account disclosure:

In thousands of AUD	Company	
	2025	2024
Adjusted franking account balance	9,758	7,807

Note 23. Financial instruments

Capital risk management

The consolidated entity manages its capital to ensure that controlled entities will be able to continue as a going concern while maximising the return to stakeholders through the optimisation of treasury management.

The capital structure of the consolidated entity consists of cash and cash equivalents and equity attributable to equity holders of the company, comprising issued capital, reserves, and retained earnings as disclosed in Notes 10 and 22, respectively.

Bank Guarantee

At 30 June 2025, the total value of cash backed guarantee provided was \$280,000 (2024: \$1,110,000).

Material accounting policies

Details of the material accounting policies and methods adopted, including the criteria for recognition, the basis of measurement and the basis on which income and expenses are recognized, in respect of each class of financial asset, financial liability and equity instrument are disclosed in Note 1 to the Financial Report.

Financial risk management objectives

The Board of Directors has overall responsibility for the establishment and oversight of the consolidated entity's financial management framework. The Board has an established Audit and Risk Committee, which is responsible for developing and monitoring the consolidated entity's financial management policies. The Committee provides regular reports to the Board of Directors on its activities.

The Audit and Risk Committee oversees how Management monitors compliance with risk management policies and procedures and reviews the adequacy of the risk management framework in relation to the risks. The main risks arising from the consolidated entity's financial instruments are currency risk, credit risk, liquidity risk and cash flow interest rate risk.

Market risk

The consolidated entity's activities expose it primarily to the financial risks of changes in foreign currency exchange rates and cash flow interest rate risks.

Foreign currency risk management

The consolidated entity undertakes certain transactions denominated in foreign currencies, hence exposures to exchange rate fluctuations arise.

The carrying amount of the consolidated entity's foreign currency denominated monetary assets and monetary liabilities at the reporting date that are denominated in a currency that is different to the functional currency of the respective entities undertaking the transactions is as follows:

In thousands of AUD	Consolidated			
	Liabilities		Assets	
	2025	2024	2025	2024
US Dollar	833	1,235	4,670	5,173
Sterling	-	-	76	116
Euro	-	-	1,756	1,819

Note 23. Financial instruments (continued)

Foreign currency sensitivity

At 30 June 2025, if the US Dollar, Sterling or Euro weakened or strengthened against the Australian dollar by the percentage shown, with all other variables held constant, net profit for the year would increase (decrease) by the following based on the change in the exchange rate against the Australian dollar.

In thousands of AUD	Consolidated			
	Net (loss)/profit before tax		Equity	
	2025	2024	2025	2024
US Dollar	384	438	384	438
Sterling	8	13	8	13
Euro	176	202	176	202

Change in currency (i) – 10% decrease.

In thousands of AUD	Consolidated			
	Net (loss)/profit before tax		Equity	
	2025	2024	2025	2024
US Dollar	(384)	(358)	(384)	(358)
Sterling	(8)	(11)	(8)	(11)
Euro	(176)	(165)	(176)	(165)

Change in currency (i) – 10% increase.

The sensitivity analysis has been based on the sensitivity rates used when reporting foreign currency risk internally to key management personnel and represents management's assessment of the possible change in foreign exchange rates based on historical volatility.

In addition to the above, there is also an A\$24.8 million (2024: A\$35.1 million) intercompany receivable in the parent entity at 30 June, denominated in US dollars, which eliminates on consolidation. The gain or loss on revaluation of the intercompany balance to Australian dollars is not eliminated and is therefore recorded through profit and loss. A 10% decrease in the Australian dollar against the US dollar would result in a A\$2.5 million (2024: A\$3.6 million) increase to net profit before tax and equity, whilst a 10% increase would result in a A\$2.5 million (2024: A\$3.6 million) decrease to net profit before tax and equity.

In management's opinion, the sensitivity analysis is not fully representative of the inherent foreign exchange risk as the year end exposure does not necessarily reflect the exposure during the course of the year. The consolidated entity includes certain subsidiaries whose functional currencies are different to the consolidated entity presentation currency. The main operating entities outside of Australia are based in the United States, the United Kingdom, Germany, and Singapore. As stated in the consolidated entity's accounting policies per Note 1, on consolidation the assets and liabilities of these entities are translated into Australian dollars at exchange rates prevailing at the year-end date. The income and expenses of these entities are translated at the average exchange rates for the year. Exchange differences arising are classified as equity and are transferred to a foreign exchange translation reserve. The consolidated entity's future reported profits could therefore be impacted by changes in rates of exchange between the Australian Dollar and United States Dollar, UK Sterling, Euro, and Singapore Dollar each.

Note 23. Financial instruments (continued)

Credit risk management

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the consolidated entity. The consolidated entity has adopted a policy of only dealing with creditworthy counterparties as a means of mitigating the risk of financial loss from defaults.

Trade receivables consist of a large number of customers, spread across diverse industries and geographical areas. The largest single counterparty balance with any one customer at 30 June 2025 was \$1.5 million (2024: \$1.3 million). Ongoing credit evaluation is performed on the financial condition of accounts.

The credit risk on liquid funds is limited because the counterparties are banks with high credit ratings assigned by international credit-rating agencies.

Liquidity risk management

Ultimate responsibility for liquidity risk management rests with the Board of Directors, who have built an appropriate liquidity risk management framework for the management of the consolidated entity's short, medium, and long-term funding and liquidity management requirements.

The consolidated entity manages liquidity risk by maintaining adequate reserves, by continuously monitoring forecast and actual cash flows and matching the maturity profiles of financial assets and liabilities.

All trade and other payables shown in Note 18 carry no interest obligation.

Fair value of financial instruments

The carrying value of financial assets and financial liabilities of the consolidated entity is a reasonable approximation of their fair value.

For non-current trade debtors Integrated Research has considered a discount rate to recognise the net present value of the debtors. Level 3 inputs have been considered including corporate borrowing rates, size of the customer and jurisdiction of the customer. A discounted cashflow model was used to derive the fair value. The range of discount rates was between 3.5% to 7.5%. The carrying value of non-current trade receivables of the consolidated entity was a reasonable approximation of their fair value.

Note 24. Consolidated entities

	Country of incorporation	Ownership interest	
		2025	2024
Parent entity:			
Integrated Research Limited	Australia		
Subsidiaries of Integrated Research Limited:			
Integrated Research Inc	USA	100%	100%
Integrated Research Singapore Pte Limited	Singapore	100%	100%
Integrated Research UK Limited	UK	100%	100%
Subsidiaries of Integrated Research UK Limited:			
Integrated Research Germany GmbH	Germany	100%	100%

Note 25. Reconciliation of cash flows from operating activities

In thousands of AUD	Consolidated	
	2025	2024
Profit/(Loss) for the year	13,358	27,130
Depreciation and amortisation	421	112
Provision for expected credit loss	128	(243)
Interest received	(3,062)	(2,321)
Interest paid	101	96
Share-based payments expense	1,591	1,556
Gain on sale of testing business	(1,218)	
Net exchange differences	384	(3)
Change in operating assets and liabilities:		
(Increase)/decrease in trade debtors	(312)	(9,848)
(Increase)/decrease in future income tax benefit	686	(1,218)
(Increase)/decrease in other operating assets	203	418
Increase/(decrease) in trade and other payables	(360)	(1,832)
Increase/(decrease) in other operating liabilities	(2,379)	(161)
Increase/(decrease) in provision for income taxes payable	(14)	(115)
Increase/(decrease) in other provisions	(848)	(527)
Net cash from operating activities	8,679	13,044

Note 26. Key management personnel disclosures

Key management personnel compensation

The key management personnel compensation is as follows:

In thousands of AUD	Consolidated	
	2025	2024
Short-term benefits	1,476,650	1,755,478
Post-employment benefits	114,496	113,038
Long term benefits	12,699	11,496
Equity compensation benefits	38,608	68,858
Termination benefits	176,061	-
	1,818,514	1,948,870

Refer to note 27. Related parties for transactions between the company and key management personnel.

Note 27. Related parties

At 30 June 2025 Mr. Steve Killelea, the founder of IR, owned either directly or indirectly 29.25% of the Company (2024: 29.91%).

Non-Executive Director Mark Brayan provided strategic advisory services to the Company through a consultancy agreement during the reporting period. The total value of these services for the year was \$42,500 (2024: \$31,250). The services commenced in June 2024 and completed in October 2024.

Apart from the details disclosed in this note, there were no other transactions between key management personnel, or their personally related entities, and the Company.

Note 28. Parent entity disclosures

Financial Position

In thousands of AUD	Parent Entity	
	2025	2024
Assets		
Current assets	78,870	70,916
Non-current assets	4,068	3,541
Total Assets	82,938	74,457
Liabilities		
Current Liabilities	6,416	7,324
Non-current liabilities	1,563	1,217
Total Liabilities	8,455	8,541
Net Assets	74,959	65,916
Equity		
Issued Capital	1,667	1,667
Employee benefits Reserve	9,901	8,310
Retained Earnings	63,391	55,939
Total Equity	74,959	65,916

Financial Performance

In thousands of AUD	Parent Entity	
	2025	2024
Profit for the year	10,641	24,366
Other comprehensive income	-	-
Total comprehensive income	10,641	24,366

Investments in subsidiaries are included at cost.

Note 29. Subsequent events

Other than Dividends in note 22, there have been no transaction or event of a material or unusual nature that has arisen in the interval between the end of the financial year and the date of this report which is likely, in the opinion of the Directors of the Company, to affect significantly the operations of the Company, the results of those operations, or the state of affairs of the Company, in future financial years.

For personal use only

Consolidated entity disclosure statement

As at 30 June 2025

Entity name	Entity type	Body corporate Country of incorporation	Body corporate % of share capital held	Country of tax residence
Parent entity:				
Integrated Research Limited	Body Corporate	Australia		Australia
Subsidiaries of Integrated Research Limited:				
Integrated Research Inc	Body Corporate	USA	100%	Australia
Integrated Research Singapore Pte Limited	Body Corporate	Singapore	100%	Australia
Integrated Research UK Limited	Body Corporate	UK	100%	Australia
Subsidiaries of Integrated Research UK Limited:				
Integrated Research Germany GmbH	Body Corporate	Germany	100%	Australia

Directors' Declaration

In accordance with a resolution of the Directors of Integrated Research Limited, we state that:

1. In the opinion of the Directors:

- a) the Financial Report and notes of Integrated Research Limited for the financial year ended 30 June 2025 are in accordance with the Corporations Act 2001, including:
 - i) giving a true and fair view of the consolidated entity's financial position as at 30 June 2025 and of its performance for the year ended on that date; and
 - ii) complying with Accounting Standards and the Corporations Regulations 2001.
- b) the Financial Report and notes also comply with International Financial Reporting Standards as disclosed in Note 1; and
- c) there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.
- d) the consolidated entity disclosure statement required by section 295(3A) of the Corporations Act is true and correct.

2. This declaration has been made after receiving the declarations required to be made to the Directors by the chief executive officer and chief financial officer in accordance with section 295A of the Corporations Act 2001 for the financial year ended 30 June 2025.

This declaration is made in accordance with a resolution of the Directors.



Peter Lloyd


Chair
26 August 2025
Sydney

Auditor's independence declaration to the Directors of Integrated Research Limited


As lead auditor for the audit of the financial report of Integrated Research Limited for the financial year ended 30 June 2025, I declare to the best of my knowledge and belief, there have been:

- a. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the audit;
- b. No contraventions of any applicable code of professional conduct in relation to the audit; and
- c. No non-audit services provided that contravene any applicable code of professional conduct in relation to the audit.

This declaration is in respect of Integrated Research Limited and the entities it controlled during the financial year.



Ernst & Young



Simon Hannigan
Partner
26 August 2025



**Shape the future
with confidence**

Ernst & Young
200 George Street
Sydney NSW 2000 Australia
GPO Box 2646 Sydney NSW 2001

Tel: +61 2 9248 5555
Fax: +61 2 9248 5959
ey.com/au

Independent auditor's report to the members of Integrated Research Limited

Report on the audit of the financial report

Opinion

We have audited the financial report of Integrated Research Limited (the Company) and its subsidiaries (collectively the Group), which comprises the consolidated statement of financial position as at 30 June 2025, the consolidated statement of comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the year then ended, notes to the financial statements, including material accounting policy information, the consolidated entity disclosure statement and the directors' declaration.

In our opinion, the accompanying financial report of the Group is in accordance with the *Corporations Act 2001*, including:

- a. Giving a true and fair view of the consolidated financial position of the Group as at 30 June 2025 and of its consolidated financial performance for the year ended on that date; and
- b. Complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial report of the current year. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, but we do not provide a separate opinion on these matters. For each matter below, our description of how our audit addressed the matter is provided in that context.

We have fulfilled the responsibilities described in the *Auditor's responsibilities for the audit of the financial report* section of our report, including in relation to these matters. Accordingly, our audit included the performance of procedures designed to respond to our assessment of the risks of material misstatement of the financial report. The results of our audit procedures, including the procedures performed to address the matters below, provide the basis for our audit opinion on the accompanying financial report.

For personal use only

Shape the future
with confidence

Revenue recognition for multiple-element arrangements

Why significant	How our audit addressed the key audit matter
<p>For the year ended 30 June 2025 the Group's revenue streams consist of Licence fees \$44.6 million, Maintenance fees \$13.2 million, Subscription fees \$3.9 million, Testing solution services \$2.7 million and Professional services \$3.8 million, as presented in the consolidated statement of comprehensive income, and disclosed in Note 1 to the financial statements.</p> <p>The majority of the Group's sales contracts involve multiple-element arrangements, for example a single software sales transaction that combines the delivery of a software license and rendering of maintenance and other professional services.</p> <p>Revenue recognition for multiple-element arrangements was considered to be a key audit matter due to the complexity of the multi-element contracts and the judgment required to allocate the revenue amongst respective contracted activities.</p>	<p>Our audit procedures included the following:</p> <ul style="list-style-type: none"> ▶ Assessment of the appropriateness of the Group's revenue recognition accounting policies relating to multi-element arrangements in accordance with the relevant requirements of AASB15 <i>Revenue from contracts with customers</i>. ▶ For a sample of contracts we assessed; <ul style="list-style-type: none"> • the Group's identification and separation of each contract element, including whether the allocation of total contract revenue to each element in the multiple-element arrangements is correct based on the underlying contract terms. • whether the revenue recognition criteria of each element in the multiple-element arrangements had been met in accordance with AASB 15, which included the determination of whether the control associated with the relevant licensed software passed to the customer in the reporting period. ▶ Assessment of the adequacy and appropriateness of the disclosures included in the Notes to the financial report.

Information other than the financial report and auditor's report thereon

The directors are responsible for the other information. The other information comprises the information included in the Company's 2025 annual report other than the financial report and our auditor's report thereon. We obtained the directors' report, the remuneration report and the Corporate Governance Statement that are to be included in the annual report, prior to the date of this auditor's report, and we expect to obtain the remaining sections of the annual report after the date of this auditor's report.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon, with the exception of the Remuneration Report and our related assurance opinion.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

For personal use only



**Shape the future
with confidence**

If, based on the work we have performed on the other information obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the directors for the financial report

The directors of the Company are responsible for the preparation of:

- ▶ The financial report (other than the consolidated entity disclosure statement) that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001*; and
- ▶ The consolidated entity disclosure statement that is true and correct in accordance with the *Corporations Act 2001*; and

for such internal control as the directors determine is necessary to enable the preparation of:

- ▶ The financial report (other than the consolidated entity disclosure statement) that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and
- ▶ The consolidated entity disclosure statement that is true and correct and is free of misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters relating to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- ▶ Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- ▶ Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.

For personal use only

**Shape the future
with confidence**

- ▶ Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- ▶ Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- ▶ Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.
- ▶ Plan and perform the Group audit to obtain sufficient appropriate audit evidence regarding the financial information of the entities or business units within the Group as a basis for forming an opinion on the Group financial report. We are responsible for the direction, supervision and review of the audit work performed for the purposes of the Group audit. We remain solely responsible for our audit opinion.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated to the directors, we determine those matters that were of most significance in the audit of the financial report of the current year and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on the audit of the Remuneration Report

Opinion on the Remuneration Report

We have audited the Remuneration Report included in pages 15 to 34 of the directors' report for the year ended 30 June 2025.

In our opinion, the Remuneration Report of Integrated Research Limited for the year ended 30 June 2025, complies with section 300A of the *Corporations Act 2001*.

Responsibilities

The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our



**Shape the future
with confidence**

responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

A handwritten signature in cursive script that reads 'Ernst + Young'.

Ernst & Young

A handwritten signature in cursive script that reads 'Simon Hannigan'.

Simon Hannigan
Partner
Sydney
26 August 2025

For personal use only